Follow-up of Pediatric Patients With Renovascular Hypertension in Türki̇ye

Follow-up of Pediatric Patients With Renovascular Hypertension in Türki̇ye | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Follow-up of Pediatric Patients With Renovascular Hypertension in Türki̇ye Cemaliye Başaran, Aslıhan Kara, Özde Nisa Türkkan, Pelin Abdal Yıldırım, and 22 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8117756/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background We aimed to evaluate the treatment and follow-up approaches used in children diagnosed with renovascular hypertension (RVHT). Methods Data from 72 patients diagnosed with RVHT in 18 centers were evaluated retrospectively. Age, blood pressure and complaints at admission, imaging methods, medications, surgical intervention methods, subsequent progression of blood pressure, and complications were questioned. Results The mean age at admission was 10.04 ± 4.88 years, the systolic blood pressure SDS was 2.25 ± 0.31, and the diastolic blood pressure SDS was 2.04 ± 0.46. Although all patients were diagnosed with at least one angiographic examination, Doppler ultrasonography was normal in 39.7% of the patients. Of the patients, 44.4% had idiopathic renal artery stenosis, 8.3% had neurofibromatosis, 26.4% had fibromuscular dysplasia, 12.5% had Takayasu arteritis, 4.2% had mid-aortic syndrome, and 4.2% had renal artery stenosis in the transplanted kidney. 55.6% of the patients were asymptomatic at the time of diagnosis. 81.5% of the patients were using two or more antihypertensive drugs before surgery. 22.2% had left ventricular hypertrophy. 43.1% of the patients did not undergo any surgical intervention. 23.6% underwent balloon surgery, 56.9% had stents, 1.4% had balloons and stents, and 20.8% had angioplasty. The need for antihypertensive drugs decreased or was eliminated in 61.1% of the patients after the procedure. At the last visit, 19.4% were followed without treatment, while 22.2% were using a single antihypertensive drug. Conclusions Since most patients with RVHT are asymptomatic at first presentation, it was concluded that blood pressure measurement is very important. In addition, the number of antihypertensives decreased significantly after an interventional procedure. Figures Figure 1 INTRODUCTION Renovascular hypertension (RVHT) represents a rare but clinically significant cause of secondary hypertension in the pediatric population [ 1 ]. Unlike primary (essential) hypertension, RVHT is characterized by structural or functional abnormalities of the renal vasculature. Stenosis of the renal arteries leads to renal hypoperfusion, triggering the release of renin from the juxtaglomerular apparatus. This initiates the conversion of angiotensinogen to angiotensin I, which is subsequently converted to angiotensin II by angiotensin-converting enzyme (ACE) [ 2 ]. Angiotensin II induces vasoconstriction of the renal efferent arterioles, increasing glomerular filtration pressure and systemic arterial pressure, ultimately resulting in activation of the renin-angiotensin-aldosterone system (RAAS) and the development of sustained hypertension [ 3 ]. Early and accurate diagnosis of RVHT in children remains challenging, as the condition frequently presents with nonspecific clinical signs and is often discovered incidentally in asymptomatic children with refractory hypertension [ 4 ]. Several studies have reported that between 26% and 70% of pediatric RVHT cases are identified during evaluations for resistant hypertension, highlighting the risk of delayed diagnosis and subsequent treatment failure [ 5 ]. If left untreated or insufficiently managed, pediatric RVHT significantly elevates the risk of serious long-term cardiovascular complications, including myocardial infarction, stroke, and chronic kidney disease in adulthood. Therefore, prompt diagnosis and appropriate intervention are critical to minimize irreversible target organ damage and improve long-term clinical outcomes. The optimal management strategy for pediatric RVHT remains a matter of ongoing clinical debate. Medical therapy alone is often inadequate in cases of significant vascular obstruction, necessitating interventional approaches such as percutaneous transluminal renal angioplasty (PTRA) or surgical revascularization. Although surgical interventions were historically regarded as the primary treatment modality, PTRA has gained increasing acceptance in recent years due to its minimally invasive nature and favorable outcomes in selected pediatric populations [ 6 ]. In response to these challenges, a national multicenter prospective study was initiated to systematically investigate the clinical characteristics, diagnostic pathways, treatment approaches, and treatment outcomes of children diagnosed with RVHT in our country. Our primary goal is to establish comprehensive, evidence-based clinical follow-up protocols for pediatric RVHT, facilitate the development of management algorithms, and provide valuable data to guide future research and improve long-term prognostic outcomes in this patient population. MATERIALS AND METHODS Study Design and Ethical Approval The study protocol was approved by the Izmir City Hospital Ethics Committee on April 15, 2022 (approval no: 2022/04–43). The study was conducted in accordance with the Declaration of Helsinki and relevant local regulations. Informed consent was not obtained from the patients due to its retrospective design. Study Population A total of 19 Pediatric Nephrology Clinics were included in the study. Pediatric patients (0–18 years old) diagnosed with RVHT and followed up in the participating centers were included in the study. Inclusion criteria were (1) confirmed RVHT diagnosis based on clinical, laboratory, and radiological findings; and (2) availability of complete medical records for retrospective data collection. Patients with insufficient clinical data or incomplete medical records were excluded from the analysis. Data Collection Demographic data including patient age, gender, body weight, and height at the time of diagnosis were collected. Symptoms at presentation, physical examination findings, blood pressure (BP) measurements, serum electrolytes, and renal function tests were evaluated. Radiologic imaging modalities used for diagnostic confirmation of RVHT such as Doppler ultrasonography, computed tomography angiography (CTA), magnetic resonance angiography (MRA), and conventional digital subtraction angiography (DSA) were also included. The location of renal artery stenosis (RAS) was documented based on imaging findings. Clinical Management and Follow-up Data on antihypertensive treatments used before diagnosis and subsequent interventional procedures (e.g., PTRA, surgical revascularization) were recorded. Information on the type and timing of surgical or interventional procedures was collected. Follow-up duration, BP monitoring results, medication dose adjustments, and clinical outcomes were also documented. Data Sources All data were abstracted retrospectively from institutional medical records, electronic health databases, radiology reports, and follow-up notes. Statistical Analysis Normality of continuous variables was assessed using the Shapiro–Wilk test. Data are presented as mean ± standard deviation (SD) for normally distributed variables and as median (minimum–maximum) for non-normally distributed variables. Between-group comparisons were performed with the independent-samples t-test or Mann–Whitney U test, as appropriate. Within-group comparisons were analyzed using the paired-samples t-test. Categorical variables were expressed as counts and percentages, and compared using Pearson’s chi-square, Fisher’s exact, or Fisher–Freeman–Halton tests. Statistical significance was set at p < 0.05. Analyses were conducted using IBM SPSS Statistics, Version 25.0 (IBM Corp., Armonk, NY, USA). RESULTS Data of 86 patients followed up for RVHT were obtained. However, patients with insufficient data and very short follow-up periods were not included in the evaluation. As a result, 72 patients were included in the study. Patients' demographic data are given in Table 1 . Table 1 Baseline characteristics of the study cohort. Variable Total (n = 72) Age, years 10.0 ± 4.9 Height SDS –0.10 ± 1.83 Weight SDS 0.14 ± 1.75 Systolic BP SDS 2.25 ± 0.31 Diastolic BP SDS 2.04 ± 0.46 Gender, n (%) Female: 30 (41.7) Male: 42 (58.3) Family history, n (%) Yes: 4 (5.5) Presenting complaint, n (%) Asymptomatic: 40 (55.6) Headache: 24 (33.3) Palpitations/Chest pain: 3 (4.2) Nosebleed: 1 (1.4) Convulsion: 1 (1.4) Urinary incontinence: 1 (1.4) Encephalopathy: 1 (2.4) Visual impairment: 1 (2.4) Diagnosis, n (%) Idiopathic: 32 (44.4 ) FMD: 19 (26.4) Neurofibromatosis: 6 (8.3) Takayasu arteritis: 9 (12.5) Midaortic syndrome: 3 (4.2) Transplant RAS: 3 (4.2) Localization of stenosis, n (%) Right: 21 (29.2) Left: 21 (29.2) Aorta: 8 (11.1) Bilateral: 19 (26.4) Kidney transplant: 3 (4.2) Values are expressed as mean ± standard deviation (SD) or number (%). SDS, standard deviation score; BP, blood pressure; FMD, fibromuscular dysplasia; RAS, renal artery stenosis Although all patients were diagnosed with at least one angiographic examination, 27 (39.7%) patients had normal renal Doppler ultrasonographic evaluation. 20 patients were diagnosed with magnetic resonance angiography (MRA), and 47 patients were diagnosed with computerized tomographic angiography (CTA). Digital Subtraction Angiography (DSA) was applied to 8 patients. Before treatment, 79.6% of patients were using two or more antihypertensive drugs. The most commonly used antihypertensive agent was calcium channel blockers (34.7%). Beta blockers were second in the list (20.5%), and ACEi/ARBs were third (20%). Left ventricular hypertrophy was present in 16 (24.6%) of 65 patients evaluated with echocardiography before treatment, retinopathy was present in 20 (27.8%) of 72 patients with fundus examination, and microalbuminuria was present in 8 (11.1%) of 72 patients with spot urine examination. While 31 (43.1%) patients did not undergo any surgical intervention, 17 (23.6%) patients underwent balloon, 5 (6.9%) underwent stent, 1 (1.4%) underwent balloon and stent, and 15 (20.8%) underwent angioplastic surgery. 3 patients underwent nephrectomy. We classified the patients into three groups: Group 1 (no procedure), Group 2 (balloon ± stent applied), and Group 3 (surgery applied). We did not observe any differences in laboratory values between the groups (Table 2 ). Since renin, plasma renin activity and aldosterone values ​​were studied in different centers and different numbes of patients, comparison between groups could not be made. Table 2 Comparison of laboratory values between patients. Variable Group 1 Group 2 Group 3 p-value WBC 8026.09 ± 2131.66 7144.17 ± 2980.69 9248.06 ± 3763.48 0.126 Hb 12.74 ± 1.69 12.92 ± 1.87 12.80 ± 2.29 0.952 Plt 292000 306000 291713 0.890 Glucose 90 (73–119) 90 (59–153) 92 (87–97) 0.900 BUN 20 (9–94) 24.25 (9–240) 28.78 (18–39) 0.524 Creatinine 0.58 (0.20–2.40) 0.45 (0.30–0.90) 0.71 (0.3–3.7) 0.198 Protein 7.40 (5.30–8.40) 7.10 (4.60–8.00) 8.89 (5.17–12.61) 0.568 Albumin 4.70 (3.20–5.00) 4.70 (2.80–5.10) 4.39 (4.18–4.61) 0.286 Sodium 138 (129–142) 138 (96–140) 137 (135–139) 0.932 Potassium 4.00 (3.2–5.8) 4.15 (2.9–5.4) 4.34 (4.12–4.56) 0.415 Chloride 102 (88–108) 102 (67–109) 102 (99–104) 0.744 Cholesterol 177 (116–237) 152 (127–342) 157 (145–169) 0.439 Triglyceride 103 (34–217) 57 (20–386) 106 (79–133) 0.882 Group 1: no procedure; Group 2: balloon ± stent intervention; Group 3: surgical procedure. In Table 3 , we evaluated the antihypertensive medications used by the patients and their responses. At the beginning, only 1.4% of the patients were not using any medication, while 18.1% were using one medication, 27.8% were using two medications, 27.8% were using three medications and 25% were using four medications. A statistically significant difference was found between the groups in terms of the total number of medications at the beginning (p = 0.017). This difference is particularly related to the high rate of two medications in Group 3 (50%) and the high rate of three medications in Group 2 (52.2%). In the final evaluation, the rate of individuals not using medication increased to 19.4%; 22.2% were using one medication, 27.8% were using two medications, 18.1% were using three medications and 12.5% ​​were using four medications. There was no statistically significant difference between the groups in terms of the distribution of the final number of medications (p = 0.242). In addition, as seen in the table, BP decreased or returned to normal by 45.2% in the no-procedure group, 69.6% in the balloon + stent group, and 88.8% in the surgical group. Table 3 Comparison of the groups without any surgical procedure, those with balloon ± stent, and those with surgical procedure according to the antihypertensives used. Variable Total (n = 72, %) Group 1 (n = 31, %) Group 2 (n = 23, %) Group 3 (n = 18, %) p-value Initial number of medications 0.017 0 1 (1.4) 1 (3.2) 0 0 1 13 (18.1) 9 (29) 3 (13) 1 (5.6) 2 20 (27.8) 8 (25.8) 3 (13) 9 (50) 3 20 (27.8) 6 (19.4) 12 (52.2) 2 (11.1) 4 18 (25) 7 (22.6) 5 (21.7) 6 (33.3) BP 0.020 Unchanged 26 (36.1) 15 (48.4) 9 (39.1) 2 (11.1) Decreased 32 (44.4) 12 (38.6) 11 (47.8) 9 (50) Returned to normal 12 (16.7) 2 (6.5) 3 (13.1) 7 (38.9) Increased 2 (2.8) 2 (6.5) - - Last number of medications 0.209 0 14 (19.4) 3 (9.7) 5 (21.7) 6 (33.3) 1 16 (22.2) 10 (32.3) 4 (17.4) 2 (11.1) 2 20 (27.8) 9 (29) 4 (17.4) 7 (38.9) 3 13 (18.1) 6 (19.4) 5 (21.7) 2 (11.1) 4 9 (12.5) 3 (9.7) 5 (21.7) 1 (5.6) Group 1: no procedure; Group 2: balloon ± stent intervention; Group 3: surgical procedure. BP, blood pressure. The mean time for BP to return to normal after the first invasive procedure was 59.0 days. The second invasive procedure was performed in 8 patients. 4 cases were initially bilateral and underwent invasive procedures on the other kidney, 2 patients underwent grafting in the same vein (one month and six months after the first procedure), and 1 patient underwent repeat balloon placement 1 month later. 1 patient underwent repeat surgery 2 days later. Blood pressure returned to normal in 62.5% of patients after the second procedure. None underwent a third procedure. No procedure was performed in 4 of the 19 bilateral RAS cases. 9 patients underwent initial balloon + stent placement, and only 3 of them underwent the contralateral procedure (2 balloon and 1 surgery). Of the 6 patients who underwent initial surgery, only 1 patient underwent contralateral surgery ( Fig. 1 ). At the end of the average follow-up period of 42.71 ± 46.59 months, 19.4% were followed up without treatment, while 22.2% were using a single antihypertensive drug at the end of the follow-up. The presence of unilateral or bilateral stenosis did not significantly differ in baseline systolic and diastolic BP SDSs. Similarly, the presence of unilateral or bilateral stenosis did not cause a significant change in patients' eGFRs during follow-up (Table 4 ). Table 4 Characteristics of unilateral and bilateral patients. Variable Unilateral (n = 53) Bilateral (n = 19) p-value Systolic BP SDS at diagnosis 2,24 ± 0,37 2,29 ± 0,13 0,505 Diastolic BP SDS at diagnosis 2,00 ± 0,49 2,15 ± 0,38 0,228 Changes in eGFR 31,48 ± 59,55 36,88 ± 35,86 0,720 BP, Blood pressure. Whether the stenosis was on the right or left did not create a significant difference in initial systolic and diastolic BP SDS or surgical requirement. However, the need for surgery was significantly higher in cases with bilateral stenosis compared to cases with unilateral stenosis (p: 0.014) (Table 5 ). Table 5 Laterality difference. Variable Right RAS n = 21 Left RAS n = 21 Bilateral n = 19 p-value Age at diagnosis 9,09 ± 5,64 10,52 ± 4,95 9,21 ± 4.10 0.632 Systolic BP SDS at diagnosis 2,23 ± 0,44 2,21 ± 0,37 2,29 ± 0,13 0.299 Diastolic BP SDS at diagnosis 1,99 ± 0,45 2,15 ± 0,28 2,15 ± 0,38 0.539 eGFR at diagnosis 154,59 ± 57,82 159,87 ± 36,43 142,71 ± 43,30 0.293 Need for surgery Yes: 10 No: 11 Yes: 10 No: 11 Yes: 15 No: 4 0.014 RAS, Renal Artery Stenosis; BP, Blood pressure. When we divided the patients into 3 groups (Group 1: no procedure; Group 2: balloon ± stent intervention; Group 3: surgical procedure) or 2 main groups (those who did not undergo the procedure (Group 1), those who underwent the procedure (Group 2 + 3), the change in eGFR between the groups was not statistically significant (Table 6 ). Table 6 eGFR changes between groups. variable Group 1 (n = 31,%) Group 2 (n = 23,%) Group 3 (n = 18,%) p-value Group 1 (n = 31,%) Group 2 + 3 (n = 41,%) p-value İnitial eGFR 107.52 ± 43.11 104.12 ± 32.19 108.43 ± 36.71 0.926 107.52 ± 43.11 106.02 ± 33.87 0.869 Last eGFR 114.46 ± 33.71 111.76 ± 32.76 124.11 ± 23.97 0.461 114.46 ± 33.71 117.60 ± 28.21 0.687 eGFR 8.78 ± 42.89 7.67 ± 39.29 13.55 ± 37.53 0.898 8.78 ± 42.89 10.46 ± 38.04 0.867 Group 1: no procedure; Group 2: balloon ± stent intervention; Group 3: surgical procedure. DISCUSSION In our study, where patients who were followed up with the diagnosis of RVHT in our country were examined retrospectively and we found that there was a significant decrease in the number of antihypertensive drugs used by patients who underwent surgery after the procedure. In addition, since most of the patients were asymptomatic at presentation, the importance of BP measurement as part of the physical examination in routine pediatric practice has been highlighted once again. The fact that renal Doppler USG was normal in most of the patients diagnosed suggests that angiographic examination should be considered when clinical suspicion arises. The most common manifestation of RVHT is resistant hypertension detected in asymptomatic patients [ 7 ]. Newborns are also often asymptomatic at first, and hypertension is often diagnosed incidentally during routine BP examinations. Rarely, heart failure, feeding intolerance, or failure to thrive may also be the first symptoms [ 8 , 9 ]. In the study by Yang et al., 32.4% of patients were asymptomatic and RAS was detected upon high BP measurements, and 27.0% had mild symptoms such as mild dizziness, headache, nausea or vomiting [ 10 ]. In the study by Green et al., most children reported non-specific symptoms such as headache and abdominal pain, and unlike adults, they had difficulty in characterizing common symptoms associated with hypertension such as tinnitus or blurred vision [ 11 ]. A retrospective study conducted in Israel noted behavioral changes in children, including hyperactivity, restlessness, and attention deficits, in the 3–12 months before the diagnosis of RVHT [ 12 ]. In our study, approximately 55.6% of the patients were asymptomatic at the time of diagnosis. The diagnosis of RVHT in children is delayed due to both the neglect of BP measurement in routine practice and the difficulties in measuring and interpreting BP [ 1 ]. In the study by Yang et al., the mean age of 37 patients was 11.51 ± 4.57 years [ 10 ]. The fact that the average age of diagnosis in our study was 10.04 supports this situation. Although the discovery of new genes continues to increase, data suggest that approximately 11–60% of RAS cases are familial [ 1 ]. In our study, 9.7% of the 41 patients for whom family data was available had a history of hypertension in their mother and/or father. In the study by Yang et al., fibromuscular dysplasia was diagnosed in 56.8% of patients, and Takayasu arteritis in 35.1. In this study, unilateral RAS was present in 78.4% of the patients, 16.2% of which were detected in a solitary kidney. The remaining 21.6% had bilateral lesions [ 10 ]. In our study, 44.4% of patients were diagnosed with idiopathic RAS. Right and left renal artery involvement was equal, and there were 19 (26.4%) cases with bilateral involvement. Although electrolyte disturbances are not sensitive markers for the diagnosis of RVHT, they are important to exclude other causes of hypertension [ 13 ]. There was no patient with electrolyte abnormalities at baseline in our study. Increased creatinine levels depend on the degree of RAS. In unilateral disease, serum creatinine concentration usually remains normal due to compensation by the healthy kidney, which may mask dysfunction in that kidney. However, bilateral disease may lead to decreased renal function due to hypoperfusion [ 14 ]. In our study, only 6 patients had an initial eGFR < 60 ml/min/1.73 m 2 . Two of them had bilateral RAS. In the study evaluating pediatric patients with RVHT, target organ damage was diagnosed in 40.5% of the patients. Hypertensive encephalopathy, hypertensive fundus lesion and LVH were found in 10.8%, 2.7% and 29.7% of the patients, respectively [ 10 ]. In our study, 24.6% of 65 patients evaluated with echocardiography had left ventricular hypertrophy, 27.8% of 72 patients with fundus examination had retinopathy, and 11.1% of 72 patients with spot urine examination had microalbuminuria. Imaging tests such as Renal Doppler USG, CTA, and MRA are increasingly used in diagnosis. The sensitivity and specificity of Doppler USG in children range from 63–90% to 68–95%, respectively [ 15 ]. CTA has better resolution than MRA, but requires radiation exposure. On the contrary, young children also require sedation for MRA. For CTA, 88% sensitivity and 81% specificity were reported, while for MRA, sensitivity was reported as 80% and specificity as 63% [ 16 ]. Two studies in pediatric patients reported that renal scintigraphy with 99mTc dimercaptosuccinic acid (DMSA) or 99mTc mercaptoacetyltriglycine (MAG3) showed sensitivity and specificity ranging from 48–73% to 68–88%, respectively, in detecting RAS [ 17 ]. DSA is the gold standard investigation method as it provides the best resolution, offers additional visualization of intrarenal vessels, and confirms the diagnosis of RAS while also allowing a therapeutic intervention [ 18 ]. On the other hand, it is an invasive procedure and the radiation dose is significantly higher than CTA [ 19 ]. In their study on children aged 0–18 years, Orman et al. showed that CTA identified all RAS cases and found a higher sensitivity and specificity (90.0% and 89.7%) of CTA for the diagnosis of RAS [ 20 ]. Saida et al also found that renal USG showed a high sensitivity (89%) for diagnosing RVHT. The sensitivity and specificity of CTA were 100% for each. Therefore, they recommended CTA as a diagnostic test for RVHT in children [ 21 ]. In our study, although all patients were diagnosed with at least one angiographic examination, renal Doppler USG evaluation was normal in 27 (39.7%) patients. This stated that Doppler ultrasonography is not an appropriate method to exclude RAS, and an angiographic evaluation should be considered when clinical suspicion arises. The most commonly used antihypertensives in treatment are calcium channel blockers and beta blockers. RAAS blockers can be used with caution, as these drugs are contraindicated due to the risk of causing renal failure if bilateral or solitary kidney RAS has not yet been excluded [ 22 ]. In addition to in-office BP monitoring, 24-hour ambulatory BP monitoring (ABPM) can provide valuable information about control [ 23 ]. Additionally, patients may need two or more antihypertensive medications to control BP elevation [ 16 ]. In our study, 79.6% of them were using two or more antihypertensive drugs. Children with RAS often have lesions amenable to therapeutic intervention [ 9 ]. Revascularization with percutaneous transluminal renal angioplasty (PTRA) or surgery is an important treatment option, with the ultimate goal of preserving renal function by restoring renal perfusion. Balloon angioplasty is generally preferred over other procedures because it is less invasive and has a lower risk of complications. Surgery is usually indicated if endovascular procedures fail, but may be the first treatment option in selected cases [ 24 ]. It is important to note that local expertise should be taken into account when determining the appropriate procedure. The literature on PTRA in young children is limited and is mostly in the form of case reports. In older children, the success rate of PTRA ranges from 50% to 100% [ 25 ]. It is not uncommon for percutaneous transluminal renal angioplasty to be repeated because of restenosis or significant residual stenosis from the previous procedure. Therefore, if BP persists or medication requirements increase and imaging findings suggest arterial narrowing, repeat angioplasty should be performed or surgical revascularization should be considered if the patient fails to respond to a repeat endovascular approach [ 22 ]. In the literature, the recurrence of stenosis after the first PTRA varies between 17% and 40% [ 26 ]. In our study, 4 patients underwent a second procedure on the same vessel; 2 of them had a graft placed on the same vessel (one month and six months after the first procedure), and1 patient underwent repeat balloon placement 1 month later. 1 patient underwent surgery 20 days later. However, the retrospective nature of our study was far from determining the indications for all these procedures. Improvement in BP control was demonstrated in 32% of pediatric patients treated with PTRA and followed for at least 1 year by Alexander et al. [ 27 ]. In a retrospective study conducted by Kurt-Sukur et al. on children under 2 years of age with RVHT, twenty patients underwent PTRA procedure and seven children underwent surgery. Of the 16 patients who underwent PTRA alone, 44% had normal BP, 38% showed improvement with the same or reduced treatment, and 19% showed no improvement. Four (57%) of the patients who underwent surgery had normal BP, two (29%) had improved BP, and one (14%) had no change in BP. In conclusion, they advocated that PTRA should be performed first in young children under 2 years of age with RVHT, since it has a low complication profile and causes significant improvement in BP, and surgery may be recommended in case of failure [ 25 ]. Another study in patients with FMD also reported a better response to PTRA [ 28 ]. In the studies, indications for PTRA were patients with greater than 60% stenosis on digital subtraction angiography (DSA), patients with poor BP control despite antihypertensive medications, and patients with a condition tolerant to PTRA. Patients with extensive RAS and Takayasu arteritis (TA) were considered off-label. Patients with active stage Takayasu arteritis (TA) with diffuse stenosis of the renal artery and elevated erythrocyte sedimentation rate and C-reactive protein levels were exempt from PTRA [ 10 ]. In our study, no intervention was performed on patients with Takayasu Arteritis. Surgical revascularization is considered by some authors to be a more definitive treatment for children with RAS because of its high success rate. In a published series of children and adolescents, surgical intervention was found to improve arterial hypertension by 70% to 82% and BP measurements by 12% to 27% [ 29 ]. In selected cases with weak or dysfunctional kidneys and unilateral disease, nephrectomy may also be performed, which can lead to long-term normotension [ 16 , 30 ]. In the study by Stadermann et al., normotension was achieved in 74% of children at one-year follow-up after surgery and in 85% at the last follow-up one to ten years later; in addition, significant reduction in the need for antihypertensive medications was observed; the median number of medications decreased from four before surgery to one at the last follow-up [ 31 ]. In our study, only 1.4% of the patients were not using any medication at the time of admission, while 18.1% were using one medication, 27.8% were using two medications, 27.8% were using three medications, and 25% were using four medications. In the final evaluation, the rate of individuals not using medication increased to 19.4%; 22.2% were using one medication, 27.8% were using two medications, 18.1% were using three medications, and 12.5% ​​were using four medications. There was no statistical difference between the groups in terms of the distribution of the final medication count. In addition, BP decreased or returned to normal by 45.2% in the no-procedure group, 69.6% in the balloon + stent group, and 88.8% in the surgical group. The right renal artery originates from the anterolateral aspect of the abdominal aorta and follows a longer, inferior, and posterior course. In contrast, the left renal artery arises at a higher level and follows a shorter, more horizontal course to the left kidney. This may predispose the right renal artery to increased mechanical stress or external compression. However, in our study, right and left localizations were equally common, and the age at diagnosis, systolic and diastolic BP SDS at diagnosis, and GFR at follow-up were not different between the two groups.While unilateral involvement may be better tolerated, bilateral involvement is generally expected to cause more severe hypertension because the existing hypoperfusion in both kidneys leads to stronger activation of the renin-angiotensin system. Occasionally, if the affected kidney is nonfunctional, nephrectomy may be amenable. In bilateral RAS, nephrectomy is not an option, and BP control is more difficult and carries greater risks. In our study, there was no significant difference between unilateral and bilateral cases in terms of systolic and diastolic BP SDS at the time of diagnosis and changes in GFR during follow-up. Additionally, when we compared eGFR values ​​between 3 groups (Group 1: no procedure; Group 2: balloon ± stent intervention; Group 3: surgical procedure) and 2 main groups (Group 1 and Group 2 + 3), we found an improvement in the final eGFR values, but the difference was not statistically significant. There is no clear indication for anticoagulant therapy in the pediatric population with RVHT. In a study conducted on children with RVHT, they stated that they used 50 U/kg low molecular weight Heparin daily for 3 days after angioplasty or stenting. They stated that aspirin was used for 6 months after angioplasty, and if a stent was placed, dual antiplatelet therapy consisting of aspirin and clopidogrel was given for 6 months, followed by lifelong aspirin [ 10 ]. In our study, although low molecular weight heparin and aspirin were used in both the balloon and/or stent groups and the surgery group, no comparison could be made because there was no standard dose and duration. Limitations of our study are its retrospective design and relatively short follow-up period. Prospective studies with longer follow-up periods, preferably until adulthood, are needed to define the actual BP monitoring in pediatric patients. In addition, due to its multicenter nature, indications for interventions etc., could not be detailed. In conclusion, RVHT should be suspected in any child with severe refractory hypertension that cannot be controlled with two or more antihypertensive drugs, especially if other suggestive findings such as an abdominal murmur are present and clinical symptoms suggestive of vascular damage in organs critical for hypertension (central nervous system, kidneys, and heart) are present. Declarations Conflicts of interest/Competing interests: The authors declare that they have no conflict of interest. Ethics approval: Ethical approval was obtained. Consent for publication: All authors consent to the publication of this manuscript. Payment/services info All authors have declared that no financial support was received from any organization for the submitted work. Authors' contributions: B KASAP DEMIR and C BASARAN conceptualized and designed the study, performed data analysis, drafted the initial manuscript, and reviewed and revised the manuscript., A KARA, ÖN TÜRKKAN, P ABDAL-YILDIRIM, E YILDIRIM, B ATMIŞ, B AKSU, S TANER, S YEL, S BAKKALOĞLU, S ÇETİNCE-ŞENSES, Y ÖZDEMİR, S YAVUZ, NM SAV, Ş ZIRHLI-SELÇUK, B GÜLHAN, H DURSUN, H NALÇACIOĞLU, RY ÇİÇEK, MK GÜRGÖZE, İ GÖKÇE, M BAYRAM, A KARABAY-BAYAZIT, N CENGİZ, E BAHAT-ÖZDOĞAN, helped collect the data for the study. References -Tullus K, Brennan E, Hamilton G, Lord R, McLaren CA, Marks SD, Roebuck DJ (2008) Renovascular hypertension in children. Lancet 371:1453–1463. 10.1016/S0140-6736(08)60626-1 . PMID: 18440428 -Samadian F, Dalili N, Jamalian A (2017) New Insights Into Pathophysiology, Diagnosis, and Treatment of Renovascular Hypertension. Iran J Kidney Dis 11:79–89 -Herrmann SM, Textor SC (2019) Renovascular Hypertension. Endocrinol Metab Clin North Am 48:765–778. 10.1016/j.ecl.2019.08.007 Epub 2019 Sep 19. PMID: 31655775; PMCID: PMC7184322 -Kanitkar M (2005) Renovascular hypertension. Indian Pediatr 42:47–54 PMID: 15695858 -Hiner LB, Falkner B (1993) Renovascular hypertension in children. Pediatr Clin North Am 40:123–140. 10.1016/s0031-3955(16)38485-1 . PMID: 8417400 -Agrawal H, Moodie D, Qureshi AM, Acosta AA, Hernandez JA, Braun MC, Justino H (2018) Interventions in children with renovascular hypertension: a 27-year retrospective single-center experience. Congenit Heart Dis 13(3):349–356. https://doi.org/10.1111/chd. 12608 -Shroff R, Roebuck DJ, Gordon I, Davies R, Stephens S, Marks S, Chan M, Barkovics M, McLaren CA, Shah V et al (2006) Angioplasty for Renovascular Hypertension in Children: 20-Year Experience. Pediatrics, 118, 268–275. 10.1542/peds.2005-2642 . PMID: 16818574 -HarerMW, Kent AL (2019) Neonatal hypertension: an educational review. Pediatr Nephrol 34:1009–1018. 10.1007/s00467-018-3996-1 . Epub 2018 Jul 5. PMID: 29974208 -Lobeck IN, Alhajjat AM, Dupree P, Racadio JM, Mitsnefes MM, Karns R, Tiao GM, Nathan JD (2018) The management of pediatric renovascular hypertension: a single center experience and review of the literature. J Pediatr Surg 53:18250–11831 Epub 2017 Dec 24. PMID: 29397961 -Yang X, Li P, Zhang B, Yan Z, Niu G, Yang M (2023) Outcomes of percutaneous transluminal renal angioplasty for pediatric renovascular hypertension: a 12-year retrospective single-center experience. Transl Pediatr. 30;12(8):1454–1463. 10.21037/tp-23-215 . Epub 2023 Aug 10. PMID: 37692538; PMCID: PMC10485649 -Green R, Gu X, Kline-Rogers E, Froehlich J, Mace P, Gray B et al (2016) Differences between the pediatric and adult presentation of fibromuscular dysplasia: Results from the US Registry. Pediatr Nephrol.;31:641 – 50. 10.1007/s00467-015-3234-z . Epub 2015 Nov 2. PMID: 26525198 -Krause I, Cleper R, Kovalski Y, Sinai L, Davidovits M (2009) Changes in behavior as an early symptom of renovascular hypertension in children. Pediatr Nephrol 24:2271–2274. 10.1007/s00467-009-1205-y Epub 2009 May 15. PMID: 19444479 -Humbert J, Roussey-Kesler G, Guerin P, LeFrançois T, Connault J, Chenouard A, Warin-Fresse K, Salomon R, Bruel A, Allain- Launay E (2015) Diagnostic and medical strategy for renovascular hypertension: report from a monocentric pediatric cohort. Eur J Pediatr 174:23–32 Epub 2014 Jun 24. PMID: 24953377 -Pytlos J, Michalczewska A, Majcher P, Furmanek M, Skrzypczyk P (2024) Renal Artery Stenosis and Mid-Aortic Syndrome in Children-A Review. J Clin Med. Nov 11;13(22):6778. 10.3390/jcm13226778 . PMID: 39597921; PMCID: PMC11594493 -Castelli PK, Dillman JR, Kershaw DB, Khalatbari S, Stanley JC, Smith EA (2014) Renal sonography with Doppler for detecting suspected pediatric renin-mediated hypertension - is it adequate? Pediatr Radiol 44:42–49. 10.1007/s00247-013-2785-z Epub 2013 Sep 15. PMID: 24037085 -de Oliveira Campos JL, Bitencourt L, Pedrosa AL, Silva DF, Lin FJJ, de Oliveira Dias LT, Simões E, Silva AC (2021) Renovascular hypertension in pediatric patients: update on diagnosis and management. Pediatr Nephrol 36(12):3853–3868. 10.1007/s00467-021-05063-2 Epub 2021 Apr 13. PMID: 33851262 -Minty I, Lythgoe MF, Gordon I (1993) Hypertension in paediatrics: can pre- and post-captopril technetium-99m dimercaptosuccinie acid renal scans exclude renovascular disease? Eur J Nucl Med 20:699–702. doi: 10.1007/BF00181761. PMID: 8404957 -Trautmann A, Roebuck DJ, McLaren CA, Brennan E, Marks SD, Tullus K (2017) Non-invasive imaging cannot replace formal angiography in the diagnosis of renovascular hypertension. Pediatr Nephrol 32(3):495–502. 10.1007/s00467-016-3501-7 Epub 2016 Oct 17. PMID: 27747454 -Marks SD, Tullus K (2012) Update on imaging for suspected renovascular hypertension in children and adolescents. Curr Hypertens Rep 14:591–595. 10.1007/s11906-012-0308-1 . PMID: 22986909 -Orman G, Masand PM, Kukreja KU, Acosta AA, Guillerman RP, Jadhav SP (2021) Diagnostic sensitivity and specificity of CT angiography for renal artery stenosis in children. Pediatr Radiol 51(3):419–426. 10.1007/s00247-020-04852-5 Epub 2020 Nov 5. PMID: 33151345 -Saida K, Kamei K, Hamada R, Yoshikawa T, Kano Y, Nagata H, Sato M, Ogura M, Harada R, Hataya H, Miyazaki O, Nosaka S, Ito S, Ishikura K (2020) A simple, refined approach to diagnosing renovascular hypertension in children: A 10-year study. Pediatr Int 62(8):937–943. 10.1111/ped.14224 Epub 2020 Jul 23. PMID: 32153091 -Meyers KE, Cahill AM, Sethna C (2014) Interventions for pediatric renovascular hypertension. Curr Hypertens Rep 16:422. 10.1007/s11906-014-0422-3 . PMID: 24522941 -Villegas L, Cahill AM, Meyers K (2020) Pediatric Renovascular Hypertension: Manifestations and Management. Indian Pediatr. 15;57(5):443–451. Epub 2020 Mar 12. PMID: 32221053 -van Twist DJL, de Leeuw PW, Kroon AA (2018) Renal artery fibromuscular dysplasia and its effect on the kidney. Hypertens Res 41:639–648. 10.1038/s41440-018-0063-z . Epub 2018 Jul 3. PMID: 29968847 -Kurt-Sukur ED, Brennan E, Davis M, Forman C, Hamilton G, Kessaris N, Marks SD, McLaren CA, Minhas K, Patel PA, Roebuck DJ, Stojanovic J, Stuart S, Tullus K (2022) Presentation, treatment, and outcome of renovascular hypertension below 2 years of age. Eur J Pediatr 181(9):3367–3375. 10.1007/s00431-022-04550-4 Epub 2022 Jul 6. PMID: 35792951; PMCID: PMC9395438 -Kari JA, Roebuck DJ, McLaren CA, Davis M, Dillon MJ, Hamilton G, Shroff R, Marks SD, Tullus K (2015) Angioplasty for renovascular hypertension in 78 children. Arch Dis Child 100(5):474–478. https://doi.org/10.1136/archd ischi ld- 2013- 305886 -Alexander A, Richmond L, Geary D, Salle JL, Amaral J, Connolly B (2017) Outcomes of percutaneous transluminal angioplasty for pediatric renovascular hypertension. J Pediatr Surg 52(3):395–399 Epub 2016 Aug 31. PMID: 27634559 -Chung H, Lee JH, Park E et al (2017) Long-Term Outcomes of Pediatric Renovascular Hypertension. Kidney Blood Press Res. 42:617 – 27. 10.1159/000481549 . Epub 2017 Sep 26. PMID: 28950261 -Stanley JC, Criado E, Upchurch GR, Brophy PD, Cho KJ, Rectenwald JE et al (2006) Pediatric renovascular hypertension: 132 primary and 30 secondary operations in 97 children. J Vasc Surg 44:1219–1228. 10.1016/j.jvs.2006.08.009 Epub 2006 Oct 20. PMID: 17055693 -Hegde S, Coulthard MG (eds) (2007) Follow-up of early unilateral nephrectomy for hypertension. Arch Dis Child Fetal Neonatal Ed. 92:F305-6. doi: 10.1136/adc.2006.104927. Epub 2006 Sep 21. PMID: 16990368; PMCID: PMC2675434 -Stadermann MB, Montini G, Hamilton G, Roebuck DJ, McLaren CA, Dillon MJ, Marks SD, Tullus K (2010) Results of surgical treatment for reno-vascular hypertension in children: 30 year single centre experience. Nephrol Dial Transpl 25:807–813. 10.1093/ndt/gfp537 Epub 2009 Oct 21. PMID: 19846390 -Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34(3):571–590. https://doi.org/10.1016/s0031- Supplementary Files YeniMicrosoftWordBelgesi.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8117756","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":557288512,"identity":"ec6e5401-801e-43da-ab1c-3f69147a54a0","order_by":0,"name":"Cemaliye Başaran","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABDUlEQVRIiWNgGAWjYLCCBwYMDAZQthyIOPCAkJYEJC3GYC0JBLUwILQkNsBEcAH+9u7EDwkFh+XM2Y8//FxRcyd9ftjhh0Bb7OR0G7BrkThzdrNEgsFhY8ueHGPJM8ee5W68nWYA1JJsbHYAuxYDidwNIC2JGw7kMEg2sB3O3Tg7AaTlQOI2XFrk327+AdRSv+H888c/G/4dTjecnf4BvxYJ3m0gWxIMbiSYSTa2HU6Ql87Bb4vEmdxtFgkG6YY7Z7wxs2zsO2y4QTqn4ECCAW6/8Lef3Xzjwx9reXP+9Mc3G74dlpefnb75w4cKOzlcWqCgGcmpYJUGOBQiQB2CKd9AUPUoGAWjYBSMMAAAcuRqBv8JbaEAAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0002-6422-7998","institution":"Izmir Katip Celebi University Faculty of Medicine: Izmir Katip Celebi Universitesi Tip Fakultesi","correspondingAuthor":true,"prefix":"","firstName":"Cemaliye","middleName":"","lastName":"Başaran","suffix":""},{"id":557288513,"identity":"4c1302bc-542a-43eb-bcaa-0fa7057a37d6","order_by":1,"name":"Aslıhan Kara","email":"","orcid":"","institution":"Fırat Üniversitesi Tıp Fakültesi: Firat Universitesi Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Aslıhan","middleName":"","lastName":"Kara","suffix":""},{"id":557288514,"identity":"2de08a71-313d-4056-84fd-f34fa51606c0","order_by":2,"name":"Özde Nisa Türkkan","email":"","orcid":"","institution":"Marmara Universitesi Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Özde","middleName":"Nisa","lastName":"Türkkan","suffix":""},{"id":557288515,"identity":"a872052c-7a82-4ba4-8c73-323f166248b6","order_by":3,"name":"Pelin Abdal Yıldırım","email":"","orcid":"","institution":"Izmir City Hospital","correspondingAuthor":false,"prefix":"","firstName":"Pelin","middleName":"Abdal","lastName":"Yıldırım","suffix":""},{"id":557288516,"identity":"525a7c63-4f0d-4054-bac6-9a9ccf171099","order_by":4,"name":"Erkam Yıldırım","email":"","orcid":"","institution":"Dokuz Eylul University Faculty of Medicine: Dokuz Eylul Universitesi Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Erkam","middleName":"","lastName":"Yıldırım","suffix":""},{"id":557288517,"identity":"eb25451a-8cb4-4c03-ac2d-bb55aaacb60b","order_by":5,"name":"Bahriye Atmış","email":"","orcid":"","institution":"Cukurova University Faculty of Medicine: Cukurova Universitesi Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Bahriye","middleName":"","lastName":"Atmış","suffix":""},{"id":557288518,"identity":"3ab32f07-de8f-42c8-a6da-17e61b7ef58a","order_by":6,"name":"Bağdagül Aksu","email":"","orcid":"","institution":"İstanbul Tıp Fakültesi İstanbul Üniversitesi: Istanbul Universitesi Istanbul Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Bağdagül","middleName":"","lastName":"Aksu","suffix":""},{"id":557288519,"identity":"544696a9-9f60-4766-b387-8b1916b990e1","order_by":7,"name":"Sevgin Taner","email":"","orcid":"","institution":"Ege Universitesi Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Sevgin","middleName":"","lastName":"Taner","suffix":""},{"id":557288520,"identity":"016e08ea-5661-4e47-81b7-a3542ce91224","order_by":8,"name":"Sibel Yel","email":"","orcid":"","institution":"Erciyes University: Erciyes Universitesi","correspondingAuthor":false,"prefix":"","firstName":"Sibel","middleName":"","lastName":"Yel","suffix":""},{"id":557288521,"identity":"5852fbed-0276-439d-8b5e-3601011539eb","order_by":9,"name":"Sevcan Bakkaloğlu","email":"","orcid":"","institution":"Gazi University: Gazi Universitesi","correspondingAuthor":false,"prefix":"","firstName":"Sevcan","middleName":"","lastName":"Bakkaloğlu","suffix":""},{"id":557288522,"identity":"8e548ef1-96e0-419f-a2b7-7b0080f354ce","order_by":10,"name":"Sibel Çetince Şenses","email":"","orcid":"","institution":"Ankara Bilkent City Hospital: Ankara Sehir Hastanesi","correspondingAuthor":false,"prefix":"","firstName":"Sibel","middleName":"Çetince","lastName":"Şenses","suffix":""},{"id":557288523,"identity":"5cf49cd6-38ab-4bb4-8195-ba6cbc1e4ade","order_by":11,"name":"Yeşim Özdemir","email":"","orcid":"","institution":"Eskişehir City Hospital","correspondingAuthor":false,"prefix":"","firstName":"Yeşim","middleName":"","lastName":"Özdemir","suffix":""},{"id":557288524,"identity":"6cf84fab-51f0-4bad-b579-f69c5b88a657","order_by":12,"name":"Sevgi Yavuz","email":"","orcid":"","institution":"istanbul başakşehir Çam ve sakura Şehir hastanesi","correspondingAuthor":false,"prefix":"","firstName":"Sevgi","middleName":"","lastName":"Yavuz","suffix":""},{"id":557288525,"identity":"016212cb-1348-4c22-b364-2dd9c3a62f3b","order_by":13,"name":"Nadide Melike Sav","email":"","orcid":"","institution":"Duzce University: Duzce Universitesi","correspondingAuthor":false,"prefix":"","firstName":"Nadide","middleName":"Melike","lastName":"Sav","suffix":""},{"id":557288526,"identity":"ef6b9679-5c06-45b6-b342-018e571bb2a7","order_by":14,"name":"Şenay Zırhlı Selçuk","email":"","orcid":"","institution":"İnönü Üniversitesi Tıp Fakültesi: Inonu Universitesi Tip fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Şenay","middleName":"Zırhlı","lastName":"Selçuk","suffix":""},{"id":557288527,"identity":"693b0586-c8b4-42d7-9630-7d98b06131c2","order_by":15,"name":"Bora Gülhan","email":"","orcid":"","institution":"Hacettepe Universitesi Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Bora","middleName":"","lastName":"Gülhan","suffix":""},{"id":557288528,"identity":"3ee99c89-070a-4dd4-8000-4c949c604434","order_by":16,"name":"Hasan Dursun","email":"","orcid":"","institution":"Prof Dr Cemil Taşcıoğlu Şehir Hastanesi: TC Saglik Bakanligi Adiyaman Istanbul Prof Dr Cemil Tascioglu Sehir Hastanesi","correspondingAuthor":false,"prefix":"","firstName":"Hasan","middleName":"","lastName":"Dursun","suffix":""},{"id":557288529,"identity":"6b9c0015-c126-459b-ac36-3c4837c6ff8a","order_by":17,"name":"Hülya Nalçacıoğlu","email":"","orcid":"","institution":"Ondokuz Mayıs Üniversitesi Tıp Fakültesi: Ondokuz Mayis Universitesi Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Hülya","middleName":"","lastName":"Nalçacıoğlu","suffix":""},{"id":557288530,"identity":"61e7761d-04e9-489b-8f0c-d1ac4df65f20","order_by":18,"name":"Rümeysa Yasemin Çiçek","email":"","orcid":"","institution":"Istanbul Bakirkoy Dr Sadi Konuk Training and Research Hospital: Istanbul Bakirkoy Dr Sadi Konuk Egitim ve Arastirma Hastanesi","correspondingAuthor":false,"prefix":"","firstName":"Rümeysa","middleName":"Yasemin","lastName":"Çiçek","suffix":""},{"id":557288531,"identity":"ae78de2b-8505-4941-8390-8331d3377b94","order_by":19,"name":"Metin Kaya Gürgöze","email":"","orcid":"","institution":"Fırat Üniversitesi Tıp Fakültesi: Firat Universitesi Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Metin","middleName":"Kaya","lastName":"Gürgöze","suffix":""},{"id":557288532,"identity":"56d698b3-8180-4453-89f7-e195a9446871","order_by":20,"name":"İbrahim Gökçe","email":"","orcid":"","institution":"Marmara Universitesi Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"İbrahim","middleName":"","lastName":"Gökçe","suffix":""},{"id":557288533,"identity":"81eadf85-652b-4146-a1a7-3668962b14fc","order_by":21,"name":"Meral Bayram","email":"","orcid":"","institution":"Dokuz Eylül Üniversitesi Tıp Fakültesi: Dokuz Eylul Universitesi Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Meral","middleName":"","lastName":"Bayram","suffix":""},{"id":557288534,"identity":"6fccd5ca-4c59-4aa1-8fdf-9703c0cf825f","order_by":22,"name":"Aysun Karabay Bayazıt","email":"","orcid":"","institution":"Cukurova University: Cukurova Universitesi","correspondingAuthor":false,"prefix":"","firstName":"Aysun","middleName":"Karabay","lastName":"Bayazıt","suffix":""},{"id":557288535,"identity":"86a0cdd2-7e4a-48f6-bd7b-c3e094b7ff10","order_by":23,"name":"Nurcan Cengiz","email":"","orcid":"","institution":"Muğla Sıtkı Koçman University: Mugla Sitki Kocman Universitesi","correspondingAuthor":false,"prefix":"","firstName":"Nurcan","middleName":"","lastName":"Cengiz","suffix":""},{"id":557288536,"identity":"0ef692f7-95ed-4441-80eb-0730d41ae5fe","order_by":24,"name":"Elif Bahat Özdoğan","email":"","orcid":"","institution":"Karadeniz Technical University: Karadeniz Teknik Universitesi","correspondingAuthor":false,"prefix":"","firstName":"Elif","middleName":"Bahat","lastName":"Özdoğan","suffix":""},{"id":557288537,"identity":"576619ae-d893-4c9d-be8d-c3172920f10e","order_by":25,"name":"Belde Kasap Demir","email":"","orcid":"","institution":"Izmir Katip Celebi University: Izmir Katip Celebi Universitesi","correspondingAuthor":false,"prefix":"","firstName":"Belde","middleName":"Kasap","lastName":"Demir","suffix":""}],"badges":[],"createdAt":"2025-11-14 19:16:29","currentVersionCode":1,"declarations":{"humanSubjects":false,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":false,"humanSubjectConsent":false,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-8117756/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8117756/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":98048720,"identity":"b80fb59d-c46d-4ec2-b115-be6582116cf5","added_by":"auto","created_at":"2025-12-12 08:35:37","extension":"pptx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":150531,"visible":true,"origin":"","legend":"","description":"","filename":"graphicalabstract01.11.2025.pptx","url":"https://assets-eu.researchsquare.com/files/rs-8117756/v1/edc0377f1336d6902e571c71.pptx"},{"id":98048715,"identity":"9a39278d-fa07-4d7f-8046-d5cf4cd762e6","added_by":"auto","created_at":"2025-12-12 08:35:37","extension":"xml","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":23257,"visible":true,"origin":"","legend":"","description":"","filename":"pnepPNEPD2501063.xml","url":"https://assets-eu.researchsquare.com/files/rs-8117756/v1/b351327970062685cef56aec.xml"},{"id":98427294,"identity":"e348b715-c76c-4e09-b320-4e23fc57c0e2","added_by":"auto","created_at":"2025-12-17 16:40:04","extension":"xml","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1046,"visible":true,"origin":"","legend":"","description":"","filename":"PNEPD250106312196.go.xml","url":"https://assets-eu.researchsquare.com/files/rs-8117756/v1/5042883c75cb7dc061ccb81a.xml"},{"id":98427622,"identity":"e5e54271-5692-404c-b370-c2f3dca1a978","added_by":"auto","created_at":"2025-12-17 16:40:53","extension":"xml","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":843,"visible":true,"origin":"","legend":"","description":"","filename":"PNEPD2501063Import.xml","url":"https://assets-eu.researchsquare.com/files/rs-8117756/v1/867b394ca28d0634635764bf.xml"},{"id":98048722,"identity":"cb580e6f-d30a-4ea5-abfc-a2f8cf38245a","added_by":"auto","created_at":"2025-12-12 08:35:37","extension":"xml","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":154608,"visible":true,"origin":"","legend":"","description":"","filename":"PNEPD25010630enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-8117756/v1/b80ffdba1a81f27b2c799bd4.xml"},{"id":98427726,"identity":"ec361a26-c3c7-4c18-8f11-a1d3f68731c2","added_by":"auto","created_at":"2025-12-17 16:41:02","extension":"eps","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":402,"visible":true,"origin":"","legend":"","description":"","filename":"drawingimage1.eps","url":"https://assets-eu.researchsquare.com/files/rs-8117756/v1/af4d51b45a2d8c3139cdb92c.eps"},{"id":98048721,"identity":"391a93e2-4350-4080-9116-d68cc59738b3","added_by":"auto","created_at":"2025-12-12 08:35:37","extension":"gif","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":43,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage1.gif","url":"https://assets-eu.researchsquare.com/files/rs-8117756/v1/372fb2cef5ed563ad3d74560.gif"},{"id":98427823,"identity":"61f6fed0-6d43-41b9-a62a-8b120995f78a","added_by":"auto","created_at":"2025-12-17 16:41:15","extension":"png","order_by":10,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":308,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-8117756/v1/fc2fb1687a8ceb6833b5dd7c.png"},{"id":98048724,"identity":"d929ae18-32e3-4114-816d-6c65c8f582ad","added_by":"auto","created_at":"2025-12-12 08:35:37","extension":"png","order_by":11,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":28517,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-8117756/v1/b66c31c36dc3cfae0f9348e4.png"},{"id":98048726,"identity":"1e5b7a59-1b60-4b40-839a-529577f9ceda","added_by":"auto","created_at":"2025-12-12 08:35:37","extension":"xml","order_by":12,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":149759,"visible":true,"origin":"","legend":"","description":"","filename":"PNEPD25010630structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-8117756/v1/0de17f40f8c4d8213d1ec8cf.xml"},{"id":98048727,"identity":"73ec3736-0169-4542-997e-196810c73b04","added_by":"auto","created_at":"2025-12-12 08:35:37","extension":"html","order_by":13,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":175363,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-8117756/v1/ea75df02905bbd8df1ecde9e.html"},{"id":98427735,"identity":"964c16cd-9173-4a97-9b05-c408b58948b6","added_by":"auto","created_at":"2025-12-17 16:41:03","extension":"jpeg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":152122,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eCases with bilateral RAS.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eRAS, Renal Artery Stenosis\u003c/em\u003e\u003c/p\u003e","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8117756/v1/46b07803063eb2de24f86dda.jpeg"},{"id":103050253,"identity":"06e511a2-1f47-4ed1-b2b0-345ac482b5f3","added_by":"auto","created_at":"2026-02-20 07:49:00","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1141600,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8117756/v1/1c481a23-fd00-4860-b102-08880739b9e3.pdf"},{"id":98427642,"identity":"15c39a3e-90c7-4699-9e78-0482dd93fd04","added_by":"auto","created_at":"2025-12-17 16:40:56","extension":"docx","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":15149,"visible":true,"origin":"","legend":"","description":"","filename":"YeniMicrosoftWordBelgesi.docx","url":"https://assets-eu.researchsquare.com/files/rs-8117756/v1/2674c66b87fd81da425998e1.docx"}],"financialInterests":"","formattedTitle":"\u003cp\u003eFollow-up of Pediatric Patients With Renovascular Hypertension in Türki̇ye\u003c/p\u003e","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003eRenovascular hypertension (RVHT) represents a rare but clinically significant cause of secondary hypertension in the pediatric population [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Unlike primary (essential) hypertension, RVHT is characterized by structural or functional abnormalities of the renal vasculature. Stenosis of the renal arteries leads to renal hypoperfusion, triggering the release of renin from the juxtaglomerular apparatus. This initiates the conversion of angiotensinogen to angiotensin I, which is subsequently converted to angiotensin II by angiotensin-converting enzyme (ACE) [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. Angiotensin II induces vasoconstriction of the renal efferent arterioles, increasing glomerular filtration pressure and systemic arterial pressure, ultimately resulting in activation of the renin-angiotensin-aldosterone system (RAAS) and the development of sustained hypertension [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eEarly and accurate diagnosis of RVHT in children remains challenging, as the condition frequently presents with nonspecific clinical signs and is often discovered incidentally in asymptomatic children with refractory hypertension [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. Several studies have reported that between 26% and 70% of pediatric RVHT cases are identified during evaluations for resistant hypertension, highlighting the risk of delayed diagnosis and subsequent treatment failure [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eIf left untreated or insufficiently managed, pediatric RVHT significantly elevates the risk of serious long-term cardiovascular complications, including myocardial infarction, stroke, and chronic kidney disease in adulthood. Therefore, prompt diagnosis and appropriate intervention are critical to minimize irreversible target organ damage and improve long-term clinical outcomes.\u003c/p\u003e\u003cp\u003eThe optimal management strategy for pediatric RVHT remains a matter of ongoing clinical debate. Medical therapy alone is often inadequate in cases of significant vascular obstruction, necessitating interventional approaches such as percutaneous transluminal renal angioplasty (PTRA) or surgical revascularization. Although surgical interventions were historically regarded as the primary treatment modality, PTRA has gained increasing acceptance in recent years due to its minimally invasive nature and favorable outcomes in selected pediatric populations [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eIn response to these challenges, a national multicenter prospective study was initiated to systematically investigate the clinical characteristics, diagnostic pathways, treatment approaches, and treatment outcomes of children diagnosed with RVHT in our country. Our primary goal is to establish comprehensive, evidence-based clinical follow-up protocols for pediatric RVHT, facilitate the development of management algorithms, and provide valuable data to guide future research and improve long-term prognostic outcomes in this patient population.\u003c/p\u003e"},{"header":"MATERIALS AND METHODS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003eStudy Design and Ethical Approval\u003c/h2\u003e\u003cp\u003e The study protocol was approved by the Izmir City Hospital Ethics Committee on April 15, 2022 (approval no: 2022/04\u0026ndash;43). The study was conducted in accordance with the Declaration of Helsinki and relevant local regulations. Informed consent was not obtained from the patients due to its retrospective design.\u003c/p\u003e\u003c/div\u003e\n\u003ch3\u003eStudy Population\u003c/h3\u003e\n\u003cp\u003eA total of 19 Pediatric Nephrology Clinics were included in the study. Pediatric patients (0\u0026ndash;18 years old) diagnosed with RVHT and followed up in the participating centers were included in the study. Inclusion criteria were (1) confirmed RVHT diagnosis based on clinical, laboratory, and radiological findings; and (2) availability of complete medical records for retrospective data collection. Patients with insufficient clinical data or incomplete medical records were excluded from the analysis.\u003c/p\u003e\n\u003ch3\u003eData Collection\u003c/h3\u003e\n\u003cp\u003eDemographic data including patient age, gender, body weight, and height at the time of diagnosis were collected. Symptoms at presentation, physical examination findings, blood pressure (BP) measurements, serum electrolytes, and renal function tests were evaluated. Radiologic imaging modalities used for diagnostic confirmation of RVHT such as Doppler ultrasonography, computed tomography angiography (CTA), magnetic resonance angiography (MRA), and conventional digital subtraction angiography (DSA) were also included. The location of renal artery stenosis (RAS) was documented based on imaging findings.\u003c/p\u003e\n\u003ch3\u003eClinical Management and Follow-up\u003c/h3\u003e\n\u003cp\u003eData on antihypertensive treatments used before diagnosis and subsequent interventional procedures (e.g., PTRA, surgical revascularization) were recorded. Information on the type and timing of surgical or interventional procedures was collected. Follow-up duration, BP monitoring results, medication dose adjustments, and clinical outcomes were also documented.\u003c/p\u003e\n\u003ch3\u003eData Sources\u003c/h3\u003e\n\u003cp\u003eAll data were abstracted retrospectively from institutional medical records, electronic health databases, radiology reports, and follow-up notes.\u003c/p\u003e\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\u003ch2\u003eStatistical Analysis\u003c/h2\u003e\u003cp\u003eNormality of continuous variables was assessed using the Shapiro\u0026ndash;Wilk test. Data are presented as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation (SD) for normally distributed variables and as median (minimum\u0026ndash;maximum) for non-normally distributed variables. Between-group comparisons were performed with the independent-samples t-test or Mann\u0026ndash;Whitney U test, as appropriate. Within-group comparisons were analyzed using the paired-samples t-test. Categorical variables were expressed as counts and percentages, and compared using Pearson\u0026rsquo;s chi-square, Fisher\u0026rsquo;s exact, or Fisher\u0026ndash;Freeman\u0026ndash;Halton tests. Statistical significance was set at p\u0026thinsp;\u0026lt;\u0026thinsp;0.05. Analyses were conducted using IBM SPSS Statistics, Version 25.0 (IBM Corp., Armonk, NY, USA).\u003c/p\u003e\u003c/div\u003e"},{"header":"RESULTS","content":"\u003cp\u003eData of 86 patients followed up for RVHT were obtained. However, patients with insufficient data and very short follow-up periods were not included in the evaluation. As a result, 72 patients were included in the study. Patients' demographic data are given in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eBaseline characteristics of the study cohort.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"2\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eVariable\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eTotal (n\u0026thinsp;=\u0026thinsp;72)\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eAge, years\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e10.0\u0026thinsp;\u0026plusmn;\u0026thinsp;4.9\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eHeight SDS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e\u0026ndash;0.10\u0026thinsp;\u0026plusmn;\u0026thinsp;1.83\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eWeight SDS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e0.14\u0026thinsp;\u0026plusmn;\u0026thinsp;1.75\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSystolic BP SDS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e2.25\u0026thinsp;\u0026plusmn;\u0026thinsp;0.31\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eDiastolic BP SDS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e2.04\u0026thinsp;\u0026plusmn;\u0026thinsp;0.46\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eGender, n (%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eFemale: 30 (41.7)\u003c/p\u003e\u003cp\u003eMale: 42 (58.3)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eFamily history, n (%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes: 4 (5.5)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePresenting complaint, n (%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eAsymptomatic: 40 (55.6)\u003c/p\u003e\u003cp\u003eHeadache: 24 (33.3)\u003c/p\u003e\u003cp\u003ePalpitations/Chest pain: 3 (4.2)\u003c/p\u003e\u003cp\u003eNosebleed: 1 (1.4)\u003c/p\u003e\u003cp\u003eConvulsion: 1 (1.4)\u003c/p\u003e\u003cp\u003eUrinary incontinence: 1 (1.4)\u003c/p\u003e\u003cp\u003eEncephalopathy: 1 (2.4)\u003c/p\u003e\u003cp\u003eVisual impairment: 1 (2.4)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eDiagnosis, n (%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eIdiopathic: 32 (44.4 )\u003c/p\u003e\u003cp\u003eFMD: 19 (26.4)\u003c/p\u003e\u003cp\u003eNeurofibromatosis: 6 (8.3)\u003c/p\u003e\u003cp\u003eTakayasu arteritis: 9 (12.5)\u003c/p\u003e\u003cp\u003eMidaortic syndrome: 3 (4.2)\u003c/p\u003e\u003cp\u003eTransplant RAS: 3 (4.2)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eLocalization of stenosis, n (%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eRight: 21 (29.2)\u003c/p\u003e\u003cp\u003eLeft: 21 (29.2)\u003c/p\u003e\u003cp\u003eAorta: 8 (11.1)\u003c/p\u003e\u003cp\u003eBilateral: 19 (26.4)\u003c/p\u003e\u003cp\u003eKidney transplant: 3 (4.2)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"2\"\u003e\u003cem\u003eValues are expressed as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation (SD) or number (%). SDS, standard deviation score; BP, blood pressure; FMD, fibromuscular dysplasia; RAS, renal artery stenosis\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eAlthough all patients were diagnosed with at least one angiographic examination, 27 (39.7%) patients had normal renal Doppler ultrasonographic evaluation. 20 patients were diagnosed with magnetic resonance angiography (MRA), and 47 patients were diagnosed with computerized tomographic angiography (CTA). Digital Subtraction Angiography (DSA) was applied to 8 patients.\u003c/p\u003e\u003cp\u003eBefore treatment, 79.6% of patients were using two or more antihypertensive drugs. The most commonly used antihypertensive agent was calcium channel blockers (34.7%). Beta blockers were second in the list (20.5%), and ACEi/ARBs were third (20%).\u003c/p\u003e\u003cp\u003eLeft ventricular hypertrophy was present in 16 (24.6%) of 65 patients evaluated with echocardiography before treatment, retinopathy was present in 20 (27.8%) of 72 patients with fundus examination, and microalbuminuria was present in 8 (11.1%) of 72 patients with spot urine examination.\u003c/p\u003e\u003cp\u003eWhile 31 (43.1%) patients did not undergo any surgical intervention, 17 (23.6%) patients underwent balloon, 5 (6.9%) underwent stent, 1 (1.4%) underwent balloon and stent, and 15 (20.8%) underwent angioplastic surgery. 3 patients underwent nephrectomy.\u003c/p\u003e\u003cp\u003eWe classified the patients into three groups: Group 1 (no procedure), Group 2 (balloon\u0026thinsp;\u0026plusmn;\u0026thinsp;stent applied), and Group 3 (surgery applied). We did not observe any differences in laboratory values between the groups (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). Since renin, plasma renin activity and aldosterone values ​​were studied in different centers and different numbes of patients, comparison between groups could not be made.\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eComparison of laboratory values between patients.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"11\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c11\" colnum=\"11\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eVariable\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u003cp\u003eGroup 1\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colspan=\"4\" nameend=\"c7\" namest=\"c4\"\u003e\u003cp\u003eGroup 2\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colspan=\"3\" nameend=\"c10\" namest=\"c8\"\u003e\u003cp\u003eGroup 3\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c11\"\u003e\u003cp\u003ep-value\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eWBC\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u003cp\u003e8026.09\u0026thinsp;\u0026plusmn;\u0026thinsp;2131.66\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c7\" namest=\"c4\"\u003e\u003cp\u003e7144.17\u0026thinsp;\u0026plusmn;\u0026thinsp;2980.69\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c10\" namest=\"c8\"\u003e\u003cp\u003e9248.06\u0026thinsp;\u0026plusmn;\u0026thinsp;3763.48\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.126\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eHb\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u003cp\u003e12.74\u0026thinsp;\u0026plusmn;\u0026thinsp;1.69\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c7\" namest=\"c4\"\u003e\u003cp\u003e12.92\u0026thinsp;\u0026plusmn;\u0026thinsp;1.87\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c10\" namest=\"c8\"\u003e\u003cp\u003e12.80\u0026thinsp;\u0026plusmn;\u0026thinsp;2.29\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.952\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePlt\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u003cp\u003e292000\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c7\" namest=\"c4\"\u003e\u003cp\u003e306000\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c10\" namest=\"c8\"\u003e\u003cp\u003e291713\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.890\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eGlucose\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u003cp\u003e90 (73\u0026ndash;119)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c7\" namest=\"c4\"\u003e\u003cp\u003e90 (59\u0026ndash;153)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c10\" namest=\"c8\"\u003e\u003cp\u003e92 (87\u0026ndash;97)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.900\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eBUN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u003cp\u003e20 (9\u0026ndash;94)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c7\" namest=\"c4\"\u003e\u003cp\u003e24.25 (9\u0026ndash;240)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c10\" namest=\"c8\"\u003e\u003cp\u003e28.78 (18\u0026ndash;39)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.524\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCreatinine\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u003cp\u003e0.58 (0.20\u0026ndash;2.40)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c7\" namest=\"c4\"\u003e\u003cp\u003e0.45 (0.30\u0026ndash;0.90)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c10\" namest=\"c8\"\u003e\u003cp\u003e0.71 (0.3\u0026ndash;3.7)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.198\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eProtein\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u003cp\u003e7.40 (5.30\u0026ndash;8.40)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c7\" namest=\"c4\"\u003e\u003cp\u003e7.10 (4.60\u0026ndash;8.00)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c10\" namest=\"c8\"\u003e\u003cp\u003e8.89 (5.17\u0026ndash;12.61)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.568\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eAlbumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u003cp\u003e4.70 (3.20\u0026ndash;5.00)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c7\" namest=\"c4\"\u003e\u003cp\u003e4.70 (2.80\u0026ndash;5.10)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c10\" namest=\"c8\"\u003e\u003cp\u003e4.39 (4.18\u0026ndash;4.61)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.286\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSodium\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u003cp\u003e138 (129\u0026ndash;142)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c7\" namest=\"c4\"\u003e\u003cp\u003e138 (96\u0026ndash;140)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c10\" namest=\"c8\"\u003e\u003cp\u003e137 (135\u0026ndash;139)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.932\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePotassium\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u003cp\u003e4.00 (3.2\u0026ndash;5.8)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c7\" namest=\"c4\"\u003e\u003cp\u003e4.15 (2.9\u0026ndash;5.4)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c10\" namest=\"c8\"\u003e\u003cp\u003e4.34 (4.12\u0026ndash;4.56)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.415\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eChloride\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u003cp\u003e102 (88\u0026ndash;108)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c7\" namest=\"c4\"\u003e\u003cp\u003e102 (67\u0026ndash;109)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c10\" namest=\"c8\"\u003e\u003cp\u003e102 (99\u0026ndash;104)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.744\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCholesterol\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u003cp\u003e177 (116\u0026ndash;237)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c7\" namest=\"c4\"\u003e\u003cp\u003e152 (127\u0026ndash;342)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c10\" namest=\"c8\"\u003e\u003cp\u003e157 (145\u0026ndash;169)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.439\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eTriglyceride\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u003cp\u003e103 (34\u0026ndash;217)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c7\" namest=\"c4\"\u003e\u003cp\u003e57 (20\u0026ndash;386)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c10\" namest=\"c8\"\u003e\u003cp\u003e106 (79\u0026ndash;133)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.882\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"11\"\u003e\u003cem\u003eGroup 1: no procedure; Group 2: balloon\u0026thinsp;\u0026plusmn;\u0026thinsp;stent intervention; Group 3: surgical procedure.\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eIn Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e, we evaluated the antihypertensive medications used by the patients and their responses. At the beginning, only 1.4% of the patients were not using any medication, while 18.1% were using one medication, 27.8% were using two medications, 27.8% were using three medications and 25% were using four medications. A statistically significant difference was found between the groups in terms of the total number of medications at the beginning (p\u0026thinsp;=\u0026thinsp;0.017). This difference is particularly related to the high rate of two medications in Group 3 (50%) and the high rate of three medications in Group 2 (52.2%). In the final evaluation, the rate of individuals not using medication increased to 19.4%; 22.2% were using one medication, 27.8% were using two medications, 18.1% were using three medications and 12.5% ​​were using four medications. There was no statistically significant difference between the groups in terms of the distribution of the final number of medications (p\u0026thinsp;=\u0026thinsp;0.242). In addition, as seen in the table, BP decreased or returned to normal by 45.2% in the no-procedure group, 69.6% in the balloon\u0026thinsp;+\u0026thinsp;stent group, and 88.8% in the surgical group.\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eComparison of the groups without any surgical procedure, those with balloon\u0026thinsp;\u0026plusmn;\u0026thinsp;stent, and those with surgical procedure according to the antihypertensives used.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"6\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eVariable\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eTotal (n\u0026thinsp;=\u0026thinsp;72, %)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eGroup 1 (n\u0026thinsp;=\u0026thinsp;31, %)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eGroup 2 (n\u0026thinsp;=\u0026thinsp;23, %)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003eGroup 3 (n\u0026thinsp;=\u0026thinsp;18, %)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c6\"\u003e\u003cp\u003ep-value\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eInitial number of medications\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.017\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1 (1.4)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1 (3.2)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e13 (18.1)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e9 (29)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e3 (13)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1 (5.6)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e2\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e20 (27.8)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e8 (25.8)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e3 (13)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e9 (50)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e3\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e20 (27.8)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e6 (19.4)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e12 (52.2)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e2 (11.1)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e18 (25)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e7 (22.6)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e5 (21.7)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e6 (33.3)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eBP\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.020\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eUnchanged\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e26 (36.1)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e15 (48.4)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e9 (39.1)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e2 (11.1)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eDecreased\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e32 (44.4)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e12 (38.6)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e11 (47.8)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e9 (50)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eReturned to normal\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e12 (16.7)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e2 (6.5)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e3 (13.1)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e7 (38.9)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eIncreased\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e2 (2.8)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e2 (6.5)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e-\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e-\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eLast number of medications\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.209\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e14 (19.4)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e3 (9.7)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e5 (21.7)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e6 (33.3)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e16 (22.2)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e10 (32.3)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e4 (17.4)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e2 (11.1)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e2\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e20 (27.8)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e9 (29)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e4 (17.4)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e7 (38.9)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e3\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e13 (18.1)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e6 (19.4)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e5 (21.7)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e2 (11.1)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e9 (12.5)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e3 (9.7)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e5 (21.7)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1 (5.6)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"6\"\u003e\u003cem\u003eGroup 1: no procedure; Group 2: balloon\u0026thinsp;\u0026plusmn;\u0026thinsp;stent intervention; Group 3: surgical procedure. BP, blood pressure.\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eThe mean time for BP to return to normal after the first invasive procedure was 59.0 days.\u003c/p\u003e\u003cp\u003eThe second invasive procedure was performed in 8 patients. 4 cases were initially bilateral and underwent invasive procedures on the other kidney, 2 patients underwent grafting in the same vein (one month and six months after the first procedure), and 1 patient underwent repeat balloon placement 1 month later. 1 patient underwent repeat surgery 2 days later.\u003c/p\u003e\u003cp\u003eBlood pressure returned to normal in 62.5% of patients after the second procedure. None underwent a third procedure.\u003c/p\u003e\u003cp\u003eNo procedure was performed in 4 of the 19 bilateral RAS cases. 9 patients underwent initial balloon\u0026thinsp;+\u0026thinsp;stent placement, and only 3 of them underwent the contralateral procedure (2 balloon and 1 surgery). Of the 6 patients who underwent initial surgery, only 1 patient underwent contralateral surgery ( Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eAt the end of the average follow-up period of 42.71\u0026thinsp;\u0026plusmn;\u0026thinsp;46.59 months, 19.4% were followed up without treatment, while 22.2% were using a single antihypertensive drug at the end of the follow-up.\u003c/p\u003e\u003cp\u003eThe presence of unilateral or bilateral stenosis did not significantly differ in baseline systolic and diastolic BP SDSs. Similarly, the presence of unilateral or bilateral stenosis did not cause a significant change in patients' eGFRs during follow-up (Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e).\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eCharacteristics of unilateral and bilateral patients.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"4\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eVariable\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eUnilateral (n\u0026thinsp;=\u0026thinsp;53)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eBilateral (n\u0026thinsp;=\u0026thinsp;19)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003ep-value\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSystolic BP SDS at diagnosis\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e2,24\u0026thinsp;\u0026plusmn;\u0026thinsp;0,37\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e2,29\u0026thinsp;\u0026plusmn;\u0026thinsp;0,13\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0,505\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eDiastolic BP SDS at diagnosis\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e2,00\u0026thinsp;\u0026plusmn;\u0026thinsp;0,49\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e2,15\u0026thinsp;\u0026plusmn;\u0026thinsp;0,38\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0,228\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eChanges in eGFR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e31,48\u0026thinsp;\u0026plusmn;\u0026thinsp;59,55\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e36,88\u0026thinsp;\u0026plusmn;\u0026thinsp;35,86\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0,720\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"4\"\u003e\u003cem\u003eBP, Blood pressure.\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eWhether the stenosis was on the right or left did not create a significant difference in initial systolic and diastolic BP SDS or surgical requirement. However, the need for surgery was significantly higher in cases with bilateral stenosis compared to cases with unilateral stenosis (p: 0.014) (Table\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e5\u003c/span\u003e).\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab5\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 5\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eLaterality difference.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"5\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eVariable\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eRight RAS\u003c/p\u003e\u003cp\u003en\u0026thinsp;=\u0026thinsp;21\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eLeft RAS\u003c/p\u003e\u003cp\u003en\u0026thinsp;=\u0026thinsp;21\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eBilateral\u003c/p\u003e\u003cp\u003en\u0026thinsp;=\u0026thinsp;19\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003ep-value\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eAge at diagnosis\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e9,09\u0026thinsp;\u0026plusmn;\u0026thinsp;5,64\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e10,52\u0026thinsp;\u0026plusmn;\u0026thinsp;4,95\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e9,21\u0026thinsp;\u0026plusmn;\u0026thinsp;4.10\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.632\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSystolic BP SDS at diagnosis\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e2,23\u0026thinsp;\u0026plusmn;\u0026thinsp;0,44\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e2,21\u0026thinsp;\u0026plusmn;\u0026thinsp;0,37\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e2,29\u0026thinsp;\u0026plusmn;\u0026thinsp;0,13\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.299\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eDiastolic BP SDS at diagnosis\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1,99\u0026thinsp;\u0026plusmn;\u0026thinsp;0,45\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e2,15\u0026thinsp;\u0026plusmn;\u0026thinsp;0,28\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e2,15\u0026thinsp;\u0026plusmn;\u0026thinsp;0,38\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.539\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eeGFR at diagnosis\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e154,59\u0026thinsp;\u0026plusmn;\u0026thinsp;57,82\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e159,87\u0026thinsp;\u0026plusmn;\u0026thinsp;36,43\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e142,71\u0026thinsp;\u0026plusmn;\u0026thinsp;43,30\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.293\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNeed for surgery\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eYes: 10\u003c/p\u003e\u003cp\u003eNo: 11\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eYes: 10\u003c/p\u003e\u003cp\u003eNo: 11\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eYes: 15\u003c/p\u003e\u003cp\u003eNo: 4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e\u003cspan type=\"BoldUnderline\" class=\"BoldUnderline\" name=\"Emphasis\"\u003e0.014\u003c/span\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"5\"\u003e\u003cem\u003eRAS, Renal Artery Stenosis; BP, Blood pressure.\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eWhen we divided the patients into 3 groups (Group 1: no procedure; Group 2: balloon\u0026thinsp;\u0026plusmn;\u0026thinsp;stent intervention; Group 3: surgical procedure) or 2 main groups (those who did not undergo the procedure (Group 1), those who underwent the procedure (Group 2\u0026thinsp;+\u0026thinsp;3), the change in eGFR between the groups was not statistically significant (Table\u0026nbsp;\u003cspan refid=\"Tab6\" class=\"InternalRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab6\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 6\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eeGFR changes between groups.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"8\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003evariable\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGroup 1\u003c/p\u003e\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;31,%)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eGroup 2\u003c/p\u003e\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;23,%)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eGroup 3\u003c/p\u003e\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;18,%)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003ep-value\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c6\"\u003e\u003cp\u003eGroup 1\u003c/p\u003e\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;31,%)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c7\"\u003e\u003cp\u003eGroup 2\u0026thinsp;+\u0026thinsp;3\u003c/p\u003e\u003cp\u003e(n\u0026thinsp;=\u0026thinsp;41,%)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c8\"\u003e\u003cp\u003ep-value\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eİnitial eGFR\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e107.52\u0026thinsp;\u0026plusmn;\u0026thinsp;43.11\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e104.12\u0026thinsp;\u0026plusmn;\u0026thinsp;32.19\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e108.43\u0026thinsp;\u0026plusmn;\u0026thinsp;36.71\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.926\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e107.52\u0026thinsp;\u0026plusmn;\u0026thinsp;43.11\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e106.02\u0026thinsp;\u0026plusmn;\u0026thinsp;33.87\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003e0.869\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eLast eGFR\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e114.46\u0026thinsp;\u0026plusmn;\u0026thinsp;33.71\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e111.76\u0026thinsp;\u0026plusmn;\u0026thinsp;32.76\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e124.11\u0026thinsp;\u0026plusmn;\u0026thinsp;23.97\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.461\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e114.46\u0026thinsp;\u0026plusmn;\u0026thinsp;33.71\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e117.60\u0026thinsp;\u0026plusmn;\u0026thinsp;28.21\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003e0.687\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eeGFR\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e8.78\u0026thinsp;\u0026plusmn;\u0026thinsp;42.89\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e7.67\u0026thinsp;\u0026plusmn;\u0026thinsp;39.29\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e13.55\u0026thinsp;\u0026plusmn;\u0026thinsp;37.53\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.898\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e8.78\u0026thinsp;\u0026plusmn;\u0026thinsp;42.89\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e10.46\u0026thinsp;\u0026plusmn;\u0026thinsp;38.04\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003e0.867\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"8\"\u003e\u003cem\u003eGroup 1: no procedure; Group 2: balloon\u0026thinsp;\u0026plusmn;\u0026thinsp;stent intervention; Group 3: surgical procedure.\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eIn our study, where patients who were followed up with the diagnosis of RVHT in our country were examined retrospectively and we found that there was a significant decrease in the number of antihypertensive drugs used by patients who underwent surgery after the procedure. In addition, since most of the patients were asymptomatic at presentation, the importance of BP measurement as part of the physical examination in routine pediatric practice has been highlighted once again. The fact that renal Doppler USG was normal in most of the patients diagnosed suggests that angiographic examination should be considered when clinical suspicion arises.\u003c/p\u003e\u003cp\u003eThe most common manifestation of RVHT is resistant hypertension detected in asymptomatic patients [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Newborns are also often asymptomatic at first, and hypertension is often diagnosed incidentally during routine BP examinations. Rarely, heart failure, feeding intolerance, or failure to thrive may also be the first symptoms [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. In the study by Yang et al., 32.4% of patients were asymptomatic and RAS was detected upon high BP measurements, and 27.0% had mild symptoms such as mild dizziness, headache, nausea or vomiting [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. In the study by Green et al., most children reported non-specific symptoms such as headache and abdominal pain, and unlike adults, they had difficulty in characterizing common symptoms associated with hypertension such as tinnitus or blurred vision [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. A retrospective study conducted in Israel noted behavioral changes in children, including hyperactivity, restlessness, and attention deficits, in the 3\u0026ndash;12 months before the diagnosis of RVHT [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. In our study, approximately 55.6% of the patients were asymptomatic at the time of diagnosis.\u003c/p\u003e\u003cp\u003eThe diagnosis of RVHT in children is delayed due to both the neglect of BP measurement in routine practice and the difficulties in measuring and interpreting BP [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. In the study by Yang et al., the mean age of 37 patients was 11.51\u0026thinsp;\u0026plusmn;\u0026thinsp;4.57 years [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. The fact that the average age of diagnosis in our study was 10.04 supports this situation.\u003c/p\u003e\u003cp\u003eAlthough the discovery of new genes continues to increase, data suggest that approximately 11\u0026ndash;60% of RAS cases are familial [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. In our study, 9.7% of the 41 patients for whom family data was available had a history of hypertension in their mother and/or father.\u003c/p\u003e\u003cp\u003eIn the study by Yang et al., fibromuscular dysplasia was diagnosed in 56.8% of patients, and Takayasu arteritis in 35.1. In this study, unilateral RAS was present in 78.4% of the patients, 16.2% of which were detected in a solitary kidney. The remaining 21.6% had bilateral lesions [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. In our study, 44.4% of patients were diagnosed with idiopathic RAS. Right and left renal artery involvement was equal, and there were 19 (26.4%) cases with bilateral involvement.\u003c/p\u003e\u003cp\u003eAlthough electrolyte disturbances are not sensitive markers for the diagnosis of RVHT, they are important to exclude other causes of hypertension [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. There was no patient with electrolyte abnormalities at baseline in our study. Increased creatinine levels depend on the degree of RAS. In unilateral disease, serum creatinine concentration usually remains normal due to compensation by the healthy kidney, which may mask dysfunction in that kidney. However, bilateral disease may lead to decreased renal function due to hypoperfusion [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. In our study, only 6 patients had an initial eGFR\u0026thinsp;\u0026lt;\u0026thinsp;60 ml/min/1.73 m\u003csup\u003e2\u003c/sup\u003e. Two of them had bilateral RAS.\u003c/p\u003e\u003cp\u003eIn the study evaluating pediatric patients with RVHT, target organ damage was diagnosed in 40.5% of the patients. Hypertensive encephalopathy, hypertensive fundus lesion and LVH were found in 10.8%, 2.7% and 29.7% of the patients, respectively [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. In our study, 24.6% of 65 patients evaluated with echocardiography had left ventricular hypertrophy, 27.8% of 72 patients with fundus examination had retinopathy, and 11.1% of 72 patients with spot urine examination had microalbuminuria.\u003c/p\u003e\u003cp\u003eImaging tests such as Renal Doppler USG, CTA, and MRA are increasingly used in diagnosis. The sensitivity and specificity of Doppler USG in children range from 63\u0026ndash;90% to 68\u0026ndash;95%, respectively [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. CTA has better resolution than MRA, but requires radiation exposure. On the contrary, young children also require sedation for MRA. For CTA, 88% sensitivity and 81% specificity were reported, while for MRA, sensitivity was reported as 80% and specificity as 63% [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Two studies in pediatric patients reported that renal scintigraphy with 99mTc dimercaptosuccinic acid (DMSA) or 99mTc mercaptoacetyltriglycine (MAG3) showed sensitivity and specificity ranging from 48\u0026ndash;73% to 68\u0026ndash;88%, respectively, in detecting RAS [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. DSA is the gold standard investigation method as it provides the best resolution, offers additional visualization of intrarenal vessels, and confirms the diagnosis of RAS while also allowing a therapeutic intervention [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. On the other hand, it is an invasive procedure and the radiation dose is significantly higher than CTA [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. In their study on children aged 0\u0026ndash;18 years, Orman et al. showed that CTA identified all RAS cases and found a higher sensitivity and specificity (90.0% and 89.7%) of CTA for the diagnosis of RAS [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. Saida et al also found that renal USG showed a high sensitivity (89%) for diagnosing RVHT. The sensitivity and specificity of CTA were 100% for each. Therefore, they recommended CTA as a diagnostic test for RVHT in children [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. In our study, although all patients were diagnosed with at least one angiographic examination, renal Doppler USG evaluation was normal in 27 (39.7%) patients. This stated that Doppler ultrasonography is not an appropriate method to exclude RAS, and an angiographic evaluation should be considered when clinical suspicion arises.\u003c/p\u003e\u003cp\u003eThe most commonly used antihypertensives in treatment are calcium channel blockers and beta blockers. RAAS blockers can be used with caution, as these drugs are contraindicated due to the risk of causing renal failure if bilateral or solitary kidney RAS has not yet been excluded [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. In addition to in-office BP monitoring, 24-hour ambulatory BP monitoring (ABPM) can provide valuable information about control [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. Additionally, patients may need two or more antihypertensive medications to control BP elevation [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. In our study, 79.6% of them were using two or more antihypertensive drugs.\u003c/p\u003e\u003cp\u003eChildren with RAS often have lesions amenable to therapeutic intervention [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Revascularization with percutaneous transluminal renal angioplasty (PTRA) or surgery is an important treatment option, with the ultimate goal of preserving renal function by restoring renal perfusion. Balloon angioplasty is generally preferred over other procedures because it is less invasive and has a lower risk of complications. Surgery is usually indicated if endovascular procedures fail, but may be the first treatment option in selected cases [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. It is important to note that local expertise should be taken into account when determining the appropriate procedure. The literature on PTRA in young children is limited and is mostly in the form of case reports. In older children, the success rate of PTRA ranges from 50% to 100% [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. It is not uncommon for percutaneous transluminal renal angioplasty to be repeated because of restenosis or significant residual stenosis from the previous procedure. Therefore, if BP persists or medication requirements increase and imaging findings suggest arterial narrowing, repeat angioplasty should be performed or surgical revascularization should be considered if the patient fails to respond to a repeat endovascular approach [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. In the literature, the recurrence of stenosis after the first PTRA varies between 17% and 40% [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. In our study, 4 patients underwent a second procedure on the same vessel; 2 of them had a graft placed on the same vessel (one month and six months after the first procedure), and1 patient underwent repeat balloon placement 1 month later. 1 patient underwent surgery 20 days later. However, the retrospective nature of our study was far from determining the indications for all these procedures.\u003c/p\u003e\u003cp\u003e Improvement in BP control was demonstrated in 32% of pediatric patients treated with PTRA and followed for at least 1 year by Alexander et al. [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. In a retrospective study conducted by Kurt-Sukur et al. on children under 2 years of age with RVHT, twenty patients underwent PTRA procedure and seven children underwent surgery. Of the 16 patients who underwent PTRA alone, 44% had normal BP, 38% showed improvement with the same or reduced treatment, and 19% showed no improvement. Four (57%) of the patients who underwent surgery had normal BP, two (29%) had improved BP, and one (14%) had no change in BP. In conclusion, they advocated that PTRA should be performed first in young children under 2 years of age with RVHT, since it has a low complication profile and causes significant improvement in BP, and surgery may be recommended in case of failure [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. Another study in patients with FMD also reported a better response to PTRA [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eIn the studies, indications for PTRA were patients with greater than 60% stenosis on digital subtraction angiography (DSA), patients with poor BP control despite antihypertensive medications, and patients with a condition tolerant to PTRA. Patients with extensive RAS and Takayasu arteritis (TA) were considered off-label. Patients with active stage Takayasu arteritis (TA) with diffuse stenosis of the renal artery and elevated erythrocyte sedimentation rate and C-reactive protein levels were exempt from PTRA [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. In our study, no intervention was performed on patients with Takayasu Arteritis. Surgical revascularization is considered by some authors to be a more definitive treatment for children with RAS because of its high success rate. In a published series of children and adolescents, surgical intervention was found to improve arterial hypertension by 70% to 82% and BP measurements by 12% to 27% [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]. In selected cases with weak or dysfunctional kidneys and unilateral disease, nephrectomy may also be performed, which can lead to long-term normotension [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]. In the study by Stadermann et al., normotension was achieved in 74% of children at one-year follow-up after surgery and in 85% at the last follow-up one to ten years later; in addition, significant reduction in the need for antihypertensive medications was observed; the median number of medications decreased from four before surgery to one at the last follow-up [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eIn our study, only 1.4% of the patients were not using any medication at the time of admission, while 18.1% were using one medication, 27.8% were using two medications, 27.8% were using three medications, and 25% were using four medications. In the final evaluation, the rate of individuals not using medication increased to 19.4%; 22.2% were using one medication, 27.8% were using two medications, 18.1% were using three medications, and 12.5% ​​were using four medications. There was no statistical difference between the groups in terms of the distribution of the final medication count. In addition, BP decreased or returned to normal by 45.2% in the no-procedure group, 69.6% in the balloon\u0026thinsp;+\u0026thinsp;stent group, and 88.8% in the surgical group.\u003c/p\u003e\u003cp\u003eThe right renal artery originates from the anterolateral aspect of the abdominal aorta and follows a longer, inferior, and posterior course. In contrast, the left renal artery arises at a higher level and follows a shorter, more horizontal course to the left kidney. This may predispose the right renal artery to increased mechanical stress or external compression. However, in our study, right and left localizations were equally common, and the age at diagnosis, systolic and diastolic BP SDS at diagnosis, and GFR at follow-up were not different between the two groups.While unilateral involvement may be better tolerated, bilateral involvement is generally expected to cause more severe hypertension because the existing hypoperfusion in both kidneys leads to stronger activation of the renin-angiotensin system. Occasionally, if the affected kidney is nonfunctional, nephrectomy may be amenable. In bilateral RAS, nephrectomy is not an option, and BP control is more difficult and carries greater risks. In our study, there was no significant difference between unilateral and bilateral cases in terms of systolic and diastolic BP SDS at the time of diagnosis and changes in GFR during follow-up. Additionally, when we compared eGFR values ​​between 3 groups (Group 1: no procedure; Group 2: balloon\u0026thinsp;\u0026plusmn;\u0026thinsp;stent intervention; Group 3: surgical procedure) and 2 main groups (Group 1 and Group 2\u0026thinsp;+\u0026thinsp;3), we found an improvement in the final eGFR values, but the difference was not statistically significant. There is no clear indication for anticoagulant therapy in the pediatric population with RVHT. In a study conducted on children with RVHT, they stated that they used 50 U/kg low molecular weight Heparin daily for 3 days after angioplasty or stenting. They stated that aspirin was used for 6 months after angioplasty, and if a stent was placed, dual antiplatelet therapy consisting of aspirin and clopidogrel was given for 6 months, followed by lifelong aspirin [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. In our study, although low molecular weight heparin and aspirin were used in both the balloon and/or stent groups and the surgery group, no comparison could be made because there was no standard dose and duration.\u003c/p\u003e\u003cp\u003eLimitations of our study are its retrospective design and relatively short follow-up period. Prospective studies with longer follow-up periods, preferably until adulthood, are needed to define the actual BP monitoring in pediatric patients. In addition, due to its multicenter nature, indications for interventions etc., could not be detailed.\u003c/p\u003e\u003cp\u003eIn conclusion, RVHT should be suspected in any child with severe refractory hypertension that cannot be controlled with two or more antihypertensive drugs, especially if other suggestive findings such as an abdominal murmur are present and clinical symptoms suggestive of vascular damage in organs critical for hypertension (central nervous system, kidneys, and heart) are present.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eConflicts of interest/Competing interests:\u003c/strong\u003e\u003cp\u003eThe authors declare that they have no conflict of interest.\u003c/p\u003e\u003c/p\u003e\u003cp\u003e\u003ch2\u003eEthics approval:\u003c/h2\u003e\u003cp\u003e Ethical approval was obtained.\u003c/p\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eConsent for publication:\u003c/strong\u003e\u003cp\u003e All authors consent to the publication of this manuscript.\u003c/p\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003ePayment/services info\u003c/strong\u003e\u003cp\u003eAll authors have declared that no financial support was received from any organization for the submitted work.\u003c/p\u003e\u003c/p\u003e\u003ch2\u003eAuthors' contributions:\u003c/h2\u003e\u003cp\u003eB KASAP DEMIR and C BASARAN conceptualized and designed the study, performed data analysis, drafted the initial manuscript, and reviewed and revised the manuscript., A KARA, \u0026Ouml;N T\u0026Uuml;RKKAN, P ABDAL-YILDIRIM, E YILDIRIM, B ATMIŞ, B AKSU, S TANER, S YEL, S BAKKALOĞLU, S \u0026Ccedil;ETİNCE-ŞENSES, Y \u0026Ouml;ZDEMİR, S YAVUZ, NM SAV, Ş ZIRHLI-SEL\u0026Ccedil;UK, B G\u0026Uuml;LHAN, H DURSUN, H NAL\u0026Ccedil;ACIOĞLU, RY \u0026Ccedil;İ\u0026Ccedil;EK, MK G\u0026Uuml;RG\u0026Ouml;ZE, İ G\u0026Ouml;K\u0026Ccedil;E, M BAYRAM, A KARABAY-BAYAZIT, N CENGİZ, E BAHAT-\u0026Ouml;ZDOĞAN, helped collect the data for the study.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003e-Tullus K, Brennan E, Hamilton G, Lord R, McLaren CA, Marks SD, Roebuck DJ (2008) Renovascular hypertension in children. Lancet 371:1453\u0026ndash;1463. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S0140-6736(08)60626-1\u003c/span\u003e\u003cspan address=\"10.1016/S0140-6736(08)60626-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. PMID: 18440428\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Samadian F, Dalili N, Jamalian A (2017) New Insights Into Pathophysiology, Diagnosis, and Treatment of Renovascular Hypertension. Iran J Kidney Dis 11:79\u0026ndash;89\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Herrmann SM, Textor SC (2019) Renovascular Hypertension. Endocrinol Metab Clin North Am 48:765\u0026ndash;778. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ecl.2019.08.007\u003c/span\u003e\u003cspan address=\"10.1016/j.ecl.2019.08.007\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003eEpub 2019 Sep 19. PMID: 31655775; PMCID: PMC7184322\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Kanitkar M (2005) Renovascular hypertension. Indian Pediatr 42:47\u0026ndash;54 PMID: 15695858\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Hiner LB, Falkner B (1993) Renovascular hypertension in children. Pediatr Clin North Am 40:123\u0026ndash;140. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s0031-3955(16)38485-1\u003c/span\u003e\u003cspan address=\"10.1016/s0031-3955(16)38485-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. PMID: 8417400\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Agrawal H, Moodie D, Qureshi AM, Acosta AA, Hernandez JA, Braun MC, Justino H (2018) Interventions in children with renovascular hypertension: a 27-year retrospective single-center experience. Congenit Heart Dis 13(3):349\u0026ndash;356. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/chd. 12608\u003c/span\u003e\u003cspan address=\"10.1111/chd. 12608\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Shroff R, Roebuck DJ, Gordon I, Davies R, Stephens S, Marks S, Chan M, Barkovics M, McLaren CA, Shah V et al (2006) Angioplasty for Renovascular Hypertension in Children: 20-Year Experience. Pediatrics, 118, 268\u0026ndash;275. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1542/peds.2005-2642\u003c/span\u003e\u003cspan address=\"10.1542/peds.2005-2642\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. PMID: 16818574\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-HarerMW, Kent AL (2019) Neonatal hypertension: an educational review. Pediatr Nephrol 34:1009\u0026ndash;1018. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00467-018-3996-1\u003c/span\u003e\u003cspan address=\"10.1007/s00467-018-3996-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2018 Jul 5. PMID: 29974208\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Lobeck IN, Alhajjat AM, Dupree P, Racadio JM, Mitsnefes MM, Karns R, Tiao GM, Nathan JD (2018) The management of pediatric renovascular hypertension: a single center experience and review of the literature. J Pediatr Surg 53:18250\u0026ndash;11831 Epub 2017 Dec 24. PMID: 29397961\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Yang X, Li P, Zhang B, Yan Z, Niu G, Yang M (2023) Outcomes of percutaneous transluminal renal angioplasty for pediatric renovascular hypertension: a 12-year retrospective single-center experience. Transl Pediatr. 30;12(8):1454\u0026ndash;1463. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.21037/tp-23-215\u003c/span\u003e\u003cspan address=\"10.21037/tp-23-215\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2023 Aug 10. PMID: 37692538; PMCID: PMC10485649\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Green R, Gu X, Kline-Rogers E, Froehlich J, Mace P, Gray B et al (2016) Differences between the pediatric and adult presentation of fibromuscular dysplasia: Results from the US Registry. Pediatr Nephrol.;31:641\u0026thinsp;\u0026ndash;\u0026thinsp;50. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00467-015-3234-z\u003c/span\u003e\u003cspan address=\"10.1007/s00467-015-3234-z\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2015 Nov 2. PMID: 26525198\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Krause I, Cleper R, Kovalski Y, Sinai L, Davidovits M (2009) Changes in behavior as an early symptom of renovascular hypertension in children. Pediatr Nephrol 24:2271\u0026ndash;2274. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00467-009-1205-y\u003c/span\u003e\u003cspan address=\"10.1007/s00467-009-1205-y\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003eEpub 2009 May 15. PMID: 19444479\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Humbert J, Roussey-Kesler G, Guerin P, LeFran\u0026ccedil;ois T, Connault J, Chenouard A, Warin-Fresse K, Salomon R, Bruel A, Allain- Launay E (2015) Diagnostic and medical strategy for renovascular hypertension: report from a monocentric pediatric cohort. Eur J Pediatr 174:23\u0026ndash;32 Epub 2014 Jun 24. PMID: 24953377\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Pytlos J, Michalczewska A, Majcher P, Furmanek M, Skrzypczyk P (2024) Renal Artery Stenosis and Mid-Aortic Syndrome in Children-A Review. J Clin Med. Nov 11;13(22):6778. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/jcm13226778\u003c/span\u003e\u003cspan address=\"10.3390/jcm13226778\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. PMID: 39597921; PMCID: PMC11594493\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Castelli PK, Dillman JR, Kershaw DB, Khalatbari S, Stanley JC, Smith EA (2014) Renal sonography with Doppler for detecting suspected pediatric renin-mediated hypertension - is it adequate? Pediatr Radiol 44:42\u0026ndash;49. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00247-013-2785-z\u003c/span\u003e\u003cspan address=\"10.1007/s00247-013-2785-z\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003eEpub 2013 Sep 15. PMID: 24037085\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-de Oliveira Campos JL, Bitencourt L, Pedrosa AL, Silva DF, Lin FJJ, de Oliveira Dias LT, Sim\u0026otilde;es E, Silva AC (2021) Renovascular hypertension in pediatric patients: update on diagnosis and management. Pediatr Nephrol 36(12):3853\u0026ndash;3868. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00467-021-05063-2\u003c/span\u003e\u003cspan address=\"10.1007/s00467-021-05063-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003eEpub 2021 Apr 13. PMID: 33851262\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Minty I, Lythgoe MF, Gordon I (1993) Hypertension in paediatrics: can pre- and post-captopril technetium-99m dimercaptosuccinie acid renal scans exclude renovascular disease? Eur J Nucl Med 20:699\u0026ndash;702. doi: 10.1007/BF00181761. PMID: 8404957\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Trautmann A, Roebuck DJ, McLaren CA, Brennan E, Marks SD, Tullus K (2017) Non-invasive imaging cannot replace formal angiography in the diagnosis of renovascular hypertension. Pediatr Nephrol 32(3):495\u0026ndash;502. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00467-016-3501-7\u003c/span\u003e\u003cspan address=\"10.1007/s00467-016-3501-7\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003eEpub 2016 Oct 17. PMID: 27747454\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Marks SD, Tullus K (2012) Update on imaging for suspected renovascular hypertension in children and adolescents. Curr Hypertens Rep 14:591\u0026ndash;595. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11906-012-0308-1\u003c/span\u003e\u003cspan address=\"10.1007/s11906-012-0308-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. PMID: 22986909\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Orman G, Masand PM, Kukreja KU, Acosta AA, Guillerman RP, Jadhav SP (2021) Diagnostic sensitivity and specificity of CT angiography for renal artery stenosis in children. Pediatr Radiol 51(3):419\u0026ndash;426. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00247-020-04852-5\u003c/span\u003e\u003cspan address=\"10.1007/s00247-020-04852-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003eEpub 2020 Nov 5. PMID: 33151345\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Saida K, Kamei K, Hamada R, Yoshikawa T, Kano Y, Nagata H, Sato M, Ogura M, Harada R, Hataya H, Miyazaki O, Nosaka S, Ito S, Ishikura K (2020) A simple, refined approach to diagnosing renovascular hypertension in children: A 10-year study. Pediatr Int 62(8):937\u0026ndash;943. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/ped.14224\u003c/span\u003e\u003cspan address=\"10.1111/ped.14224\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003eEpub 2020 Jul 23. PMID: 32153091\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Meyers KE, Cahill AM, Sethna C (2014) Interventions for pediatric renovascular hypertension. Curr Hypertens Rep 16:422. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11906-014-0422-3\u003c/span\u003e\u003cspan address=\"10.1007/s11906-014-0422-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. PMID: 24522941\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Villegas L, Cahill AM, Meyers K (2020) Pediatric Renovascular Hypertension: Manifestations and Management. Indian Pediatr. 15;57(5):443\u0026ndash;451. Epub 2020 Mar 12. PMID: 32221053\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-van Twist DJL, de Leeuw PW, Kroon AA (2018) Renal artery fibromuscular dysplasia and its effect on the kidney. Hypertens Res 41:639\u0026ndash;648. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41440-018-0063-z\u003c/span\u003e\u003cspan address=\"10.1038/s41440-018-0063-z\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2018 Jul 3. PMID: 29968847\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Kurt-Sukur ED, Brennan E, Davis M, Forman C, Hamilton G, Kessaris N, Marks SD, McLaren CA, Minhas K, Patel PA, Roebuck DJ, Stojanovic J, Stuart S, Tullus K (2022) Presentation, treatment, and outcome of renovascular hypertension below 2 years of age. Eur J Pediatr 181(9):3367\u0026ndash;3375. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00431-022-04550-4\u003c/span\u003e\u003cspan address=\"10.1007/s00431-022-04550-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003eEpub 2022 Jul 6. PMID: 35792951; PMCID: PMC9395438\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Kari JA, Roebuck DJ, McLaren CA, Davis M, Dillon MJ, Hamilton G, Shroff R, Marks SD, Tullus K (2015) Angioplasty for renovascular hypertension in 78 children. Arch Dis Child 100(5):474\u0026ndash;478. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1136/archd\u003c/span\u003e\u003cspan address=\"10.1136/archd\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003eischi ld- 2013- 305886\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Alexander A, Richmond L, Geary D, Salle JL, Amaral J, Connolly B (2017) Outcomes of percutaneous transluminal angioplasty for pediatric renovascular hypertension. J Pediatr Surg 52(3):395\u0026ndash;399 Epub 2016 Aug 31. PMID: 27634559\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Chung H, Lee JH, Park E et al (2017) Long-Term Outcomes of Pediatric Renovascular Hypertension. Kidney Blood Press Res. 42:617\u0026thinsp;\u0026ndash;\u0026thinsp;27. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1159/000481549\u003c/span\u003e\u003cspan address=\"10.1159/000481549\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2017 Sep 26. PMID: 28950261\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Stanley JC, Criado E, Upchurch GR, Brophy PD, Cho KJ, Rectenwald JE et al (2006) Pediatric renovascular hypertension: 132 primary and 30 secondary operations in 97 children. J Vasc Surg 44:1219\u0026ndash;1228. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jvs.2006.08.009\u003c/span\u003e\u003cspan address=\"10.1016/j.jvs.2006.08.009\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003eEpub 2006 Oct 20. PMID: 17055693\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Hegde S, Coulthard MG (eds) (2007) Follow-up of early unilateral nephrectomy for hypertension. Arch Dis Child Fetal Neonatal Ed. 92:F305-6. doi: 10.1136/adc.2006.104927. Epub 2006 Sep 21. PMID: 16990368; PMCID: PMC2675434\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Stadermann MB, Montini G, Hamilton G, Roebuck DJ, McLaren CA, Dillon MJ, Marks SD, Tullus K (2010) Results of surgical treatment for reno-vascular hypertension in children: 30 year single centre experience. Nephrol Dial Transpl 25:807\u0026ndash;813. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/ndt/gfp537\u003c/span\u003e\u003cspan address=\"10.1093/ndt/gfp537\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003eEpub 2009 Oct 21. PMID: 19846390\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003e-Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34(3):571\u0026ndash;590. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/s0031-\u003c/span\u003e\u003cspan address=\"10.1016/s0031-\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":true,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-8117756/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8117756/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e\u003cp\u003eWe aimed to evaluate the treatment and follow-up approaches used in children diagnosed with renovascular hypertension (RVHT).\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e\u003cp\u003eData from 72 patients diagnosed with RVHT in 18 centers were evaluated retrospectively. Age, blood pressure and complaints at admission, imaging methods, medications, surgical intervention methods, subsequent progression of blood pressure, and complications were questioned.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e\u003cp\u003eThe mean age at admission was 10.04\u0026thinsp;\u0026plusmn;\u0026thinsp;4.88 years, the systolic blood pressure SDS was 2.25\u0026thinsp;\u0026plusmn;\u0026thinsp;0.31, and the diastolic blood pressure SDS was 2.04\u0026thinsp;\u0026plusmn;\u0026thinsp;0.46. Although all patients were diagnosed with at least one angiographic examination, Doppler ultrasonography was normal in 39.7% of the patients. Of the patients, 44.4% had idiopathic renal artery stenosis, 8.3% had neurofibromatosis, 26.4% had fibromuscular dysplasia, 12.5% had Takayasu arteritis, 4.2% had mid-aortic syndrome, and 4.2% had renal artery stenosis in the transplanted kidney. 55.6% of the patients were asymptomatic at the time of diagnosis. 81.5% of the patients were using two or more antihypertensive drugs before surgery. 22.2% had left ventricular hypertrophy. 43.1% of the patients did not undergo any surgical intervention. 23.6% underwent balloon surgery, 56.9% had stents, 1.4% had balloons and stents, and 20.8% had angioplasty. The need for antihypertensive drugs decreased or was eliminated in 61.1% of the patients after the procedure. At the last visit, 19.4% were followed without treatment, while 22.2% were using a single antihypertensive drug.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e\u003cp\u003eSince most patients with RVHT are asymptomatic at first presentation, it was concluded that blood pressure measurement is very important. In addition, the number of antihypertensives decreased significantly after an interventional procedure.\u003c/p\u003e","manuscriptTitle":"Follow-up of Pediatric Patients With Renovascular Hypertension in Türki̇ye","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-12-12 08:35:32","doi":"10.21203/rs.3.rs-8117756/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"7668e77b-6991-410d-8c92-d7697a6ef29d","owner":[],"postedDate":"December 12th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2026-02-19T14:30:20+00:00","versionOfRecord":[],"versionCreatedAt":"2025-12-12 08:35:32","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8117756","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8117756","identity":"rs-8117756","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}